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S u m m a r y
Introduction
Breast cancer is the most commonly diagnosed malignancy in women in Ireland 
after non-melanoma skin cancer, with over 2 , 0 0 0  women diagnosed with the 
disease each year. It remains the leading cause of cancer-related mortalities in 
women, with an average annual rate of 644 deaths between 1994 and 2001. 
Although the mortality rate decreased between 1989 and 2006 by nearly 27%, it 
still remains one of the highest mortality rates in Europe.
Targeted therapy against the key receptors identified to date as being integral to 
the development and proliferation of breast cancers has significantly improved 
the overall and disease-free survival rates for patients. However, innate and 
acquired resistance to these therapeutic agents, including tamoxifen and 
trastuzumab, results in tumour recurrence which is not susceptible to further 
standard therapeutic interventions. Resistance to tamoxifen can occur in up to 
one quarter of patients after ten years, while the majority of patients with 
metastatic disease will develop resistance to trastuzumab within one year of 
treatment.
Resistance to tamoxifen is thought to occur through a number of proposed 
mechanisms. One such proposal is the concept of crosstalk between ER and the 
growth factor receptor pathways including the EGFR/HER2 family of receptors. 
This can result in resistance developing through a number of different 
mechanisms including Src kinase activation of the metalloproteinases with 
resultant activation of the MAPK pathway as well as Akt upregulation through 
PI3K and ras activation of ERK1 and ERK2.
While extensive in vitro research has been performed to determine how 
resistance to trastuzumab develops, the exact mechanisms remain inconclusive. 
Hypotheses include alteration in the interaction between the receptor and the 
antibody, alternative signalling through other HER or alternate pathways or 
failure to activate immune-mediated mechanisms to destroy tumour cells.
Understanding how resistance to trastuzumab develops would greatly improve 
the clinical prognosis for patients with HER2 expressing breast cancers, as it 
would enable clinicians to identify patients at risk of developing resistance and 
facilitate the tailoring of specific treatments to minimise the risk of such an 
outcome occurring.
Hypothesis
Research has highlighted the complex interactions that occur at a molecular level 
within breast cancer cells. Receptor crosstalk has been implicated in the 
development of resistance to endocrine therapies such as tamoxifen. We 
hypothesise that resistance to trastuzumab can be mediated by crosstalk between 
the growth factor signalling pathway and the steroid hormone pathway resulting 
in an uncontrolled upregulation of the steroid hormone pathway following 
trastuzumab treatment.
Aims
The overall aim of this work is to further elucidate the interactions between the 
steroid hormone and growth factor signalling pathways in breast cancer, in 
particular, to determine the effect of trastuzumab treatment on the steroid 
hormone pathway. The first objective will be to assess the effect of trastuzumab 
treatment on this pathway at a molecular level in breast cancer cells, looking at 
its effect at both a protein level and a transcriptional level. Secondly, we will 
verify our in vitro findings in breast cancer tissue samples utilising a large tissue 
microarray, assessing the clinical significance of our proposed crosstalk 
hypothesis.
Results
Protein expression levels of ER within the oestrogen sensitive MCF-7 cells was 
found to be increased following trastuzumab treatment while there was no effect 
observed in the oestrogen insensitive LCC-1 cells. Surprisingly, treatment of ER- 
negative SKBR-3 cells with trastuzumab resulted in the expression of ER.
Luciferase assay and RT-PCR was performed to assess whether trastuzumab had 
an enhancing effect on the functional activity of the steroid hormone pathway 
within the cell model. pS2, a well established ER target gene, was utilised to 
demonstrate activity. Increased levels of pS2 was observed following 
trastuzumab treatment in both the MCF-7 and SKBR-3 cell lines, with no 
difference in the LCC-1 cells.
Methylation studies were performed to determine whether they played a role in 
the expression of ER within the ER-negative SKBR-3 cells following 
trastuzumab treatment. Treatment was found to result in the demethylation of 
five CpG islands within the promoter region of the ER gene within the cells, 
thereby demonstrating that trastuzumab can result in epigenetic modifications in 
certain ER-negative cells resulting in the potential expression of a functional ER.
Immunohistochemistry staining for pS2 of a tissue microarray of almost five 
hundred breast cancer specimens was performed. Survival analysis of HER2 
positive patients who expressed pS2 showed that patients had a significantly 
increased rate of recurrence if  they received trastuzumab compared to those who 
did not. Similarly, a small cohort of patients who received trastuzumab prior to 
surgical resection were found to have significantly stronger staining for pS2 in 
their post-trastuzumab treated specimens when compared to their pre-treatment 
biopsies.
Conclusion
Resistance to trastuzumab remains a significant factor in the development of 
tumour recurrence in HER2-expressing breast cancers, resulting in reduced 
overall and disease-free survival times. To date, the exact mechanism by which 
resistance can develop remains elusive. In this work, molecular studies have 
demonstrated crosstalk between the steroid hormone and growth factor receptor 
pathways, suggesting that resistance can develop through upregulation of the 
endocrine signalling pathway. Furthermore, trastuzumab was also found to result 
in the expression of a functional ER in ER-negative cells, providing a previously 
unconsidered potential therapeutic target for these cancers. Translational studies
confirmed that the in vitro  findings were replicable within a clinical cohort, 
affecting patient prognosis.
These findings constitute a minute fragment of the complex interactions between 
the steroid hormone and growth factor receptor pathways in breast cancer. The 
plasticity of breast cancer and its ability to overcome therapeutic interventions 
through receptor crosstalk as well as its capacity to alter receptor status 
demonstrates the complex molecular mechanisms involved in the disease 
process. Resistance to therapies is likely to present a significant challenge to both 
clinicians and academics for many years to come. However, translational 
research methods, as demonstrated within this body of work are essential to 
unravel our understanding of this complex disease.
x
C h a p t e r  1
Introduction
1 . 1 In troduction  to breast cancer:
Breast cancer is the most commonly diagnosed malignancy in women in Ireland after 
non-melanoma skin cancer, with over 2 , 0 0 0  women diagnosed with the disease each 
year (Ireland 2009). The rate of increase of new cases of breast cancer has fallen 
from 5.1% per year between 1999 and 2002 to 2.0% per year between 2002 and 
2006. However, in 2006 the National Cancer Registry of Ireland predicted that the 
projected annual incidence would increase to almost 5,000 new cases by 2035 
(figure 1.1) (Ireland 2006).
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Figure 1.1: Actual and projected number of breast cancer cases per year from 1995 
to 2035 (National Cancer Registry Ireland, 2006).
Breast cancer remains the leading cause of cancer-related mortalities in women, with 
an average annual rate of 644 deaths as a result of the disease between 1994 and 
2001. While the overall number of deaths is expected to increase from 638 to 695 per 
year, the mortality rate is predicted to fall by 21 % (O'Lorcain P 2006). Indeed, 
between 1989 and 2006 the mortality rate has decreased overall by nearly 27% 
(figure 1.2) with an almost 43% reduction in mortality rate in women under the age 
of 50 years. However, it still remains one of the highest mortality rates in Europe, 
third only to Denmark and England/Wales (Autier, Boniol et al. 2010).
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Figure 1.2: Percentage changes in breast cancer mortality between 1989 and 2006 
according to the mean breast cancer mortality in 1987 to 1989. Ireland is 
highlighted by the red circle (Autier, Boniol et al. 2010).
Management of breast cancer has changed significantly over the last two decades. 
Improvements in detection techniques as well as the introduction of screening 
programmes has resulted in earlier diagnosis which, in conjunction with advances in 
surgical management and adjuvant therapies, has resulted in the improvements in 
overall survival rates. However, resistance to adjuvant therapies can develop as a 
result of the plasticity of tumour cells, with the challenge remaining to develop the 
ability to individualise treatment regimes according to tumour characteristics 
resulting in maximum patient benefit with minimal co-morbid effects and decreased 
risk of resistance developing.
1.2 Aetiology:
It is well established that breast cancer is a multi-factorial disease, with both genetic 
and environmental components identified which are associated with its development. 
Risk factors include family history, especially in first degree relatives, nulliparity, 
early menarche, late menopause as well as a previous history of breast cancer. 
Specific germline mutations are also known to significantly increase the risk of its
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occurrence. In particular the high penetrance B R C A 1  and B R C A 2  mutations are 
associated with a 40%  to 85% risk o f developing breast cancer (Blackwood and 
Weber 1998; Antoniou, Pharoah et al. 2003). Other low penetrance genes have also 
been identified which confer a high risk for developing breast cancer including 
TP53, P T E N , A T M  (Campeau, Foulkes et al. 2008) while C H E K 2 , P A L B 2  and 
BR IP1 double the risk compared to the normal population (Walsh and K in g  2007; 
Campeau, Foulkes et al. 2008). Although a number of genetic mutations have been 
identified which increase the predisposition to breast cancer, high penetrance 
B R C A 1  and B R C A 2  mutations account for only 25%  of familial breast cancer 
susceptibility with the remaining 75%  thought to be due to a large number o f  
mutations affecting low penetrance genes (Pharoah, Antoniou et al. 2002). Specific 
treatments for B R C A 1  and B R C A 2  germline mutations have yet to developed but 
poly(ADP-ribose) polymerase 1 (P A R P ) has been shown to be effective in vitro 
(Bryant, Schultz et al. 2005; Farmer, M cCabe et al. 2005) with clinical trials 
currently underway to further elucidate their benefits in these high penetrance 
mutations.
In breast cancer, there are a number o f different factors which can determine 
treatment and influence outcome. These include the tumour tissue expression of 
oestrogen receptor (E R ), progesterone receptor (P R ) and human epidermal growth 
factor receptor 2 (HER2/neu). In  particular the presence or absence o f E R  and/or 
H E R 2  can help predict the natural history and prognosis o f the tumour and can also 
offer potential therapeutic targets. However, resistance to therapies that target these 
receptors can develop indicating a poor overall prognosis for the patient. A n  
understanding o f the plasticity o f tumour cells and their ability to proliferate in the 
presence o f current therapeutic agents is essential to overcome resistance and to 
improve patient survival.
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1.3 The steroid hormone pathway
1.3.1 The oestrogen receptor
Steroid hormones including oestrogen influence a wide variety o f cellular functions 
including proliferation and differentiation by influencing specific target gene 
expression (Tsai and O'Malley 1994; Mangelsdorf, Thummel et al. 1995). Prolonged 
exposure to oestrogen, both endogenously and exogenously, has been shown to 
result in the development o f breast cancer (Colditz 1998; Hankinson, Colditz et al. 
2004). The effects o f oestrogen are mediated through E R s  which are members o f the 
nuclear receptor family (Kumar and Thompson 1999). E R  induces transcriptional 
activity in the nucleus o f cells in a number o f ways including through a 
deoxyribonucleic acid (D N A)-binding domain which interacts with specific sites in 
the promoter region of target genes known as oestrogen-responsive elements (E R E )  
(Parker 1993; Osborne, Zhao et al. 2000). After E R  was first identified over forty 
years ago, with subsequent isolation o f encoding complementary deoxyribonucleic 
acids (cD N A s), it was thought that there was only one receptor isoform (Gorski, Toft 
et al. 1968; Jensen and DeSombre 1972; Green, Walter et al. 1986; Greene. Gilna et 
al. 1986). However, the subsequent discovery o f a second subtype o f E R , classified 
as E R p  with the initial receptor now classified as E R a , indicated a more complex 
nature to the oestrogen receptor than previously perceived (Kuiper, Enmark et al. 
1996; Mosselman, Polman et al. 1996; Katzenellenbogen and Korach 1997). This 
stimulated intense interest in the role o f E R p  and how it compared to that o f ER a. In  
vitro  research revealed a significantly lower transcriptional activity in both ovarian 
and breast cancer cell lines, while its tissue distribution was found to be similar but 
not identical to that of E R a  (Kuiper, Enmark et al. 1996; Kuiper, Carlsson et al.
1997; Mclnemey, Weis et al. 1998). Indeed, they are now considered to play 
different roles in breast cancer through different D N A  enhancers, with E R a  
appearing to be the predominant regulator o f oestrogen-induced genes through its 
interaction with E R E , while ER(3 appears to have minimal interaction with E R E  
(Bieche, Parfait et al. 2001; Hewitt, Harrell et al. 2005). From henceforth within this 
thesis, E R  w ill refer only to E R a.
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1.3.2 Regulation o f ER  expression
Approximately two thirds of breast cancers express ER at time of diagnosis (Osborne 
1998). This has resulted in the development of therapies designed to interfere in the 
action of oestrogen on the ER to reduce cell proliferation and tumour growth. 
However, in the remaining one third of cancers, ER is not expressed and so is not a 
potential therapeutic target. The exact mechanism by which ER expression is lost 
remains unclear. In humans, chromosome 6  encodes for the ER protein gene which 
spans approximately 300kb. It contains eight coding regions which are transcribed 
from at least seven promoters (Kos, Reid et al. 2001). In keeping with the complex 
nature of the ER promoter, ER protein expression is known to be regulated by a 
number of molecular mechanisms including effectors of the chromatin structure. The 
ER negative phenotype could potentially result from homozygous deletion of the ER 
gene or loss of heterozygosity along with mutation of the remaining allele (Lapidus, 
Nass et al. 1998). However, homozygous deletion of the region surrounding the ER 
gene has not been identified in breast cancer. The loss of heterozygosity is not 
significantly different between ER positive and negative cancers and no significant 
gene alterations such as insertions, deletions or point mutations have been reported 
(Lapidus, Nass et al. 1998).
Epigenetic modifications are a mechanism by which loss of gene transcription can 
occur in the absence of gross mutations. There are a number of different 
modifications which can occur resulting in changes in gene expression including 
méthylation, acétylation, phosphorylation and ubiquitination. Méthylation of specific 
areas within DNA is a well described epigenetic modification by which gene 
expression is lost (Holliday and Pugh 1975). When cytosine-guanine rich areas, 
known as CpG islands, in the region of the 5’ promoter of certain genes become 
methylated, the transcriptional activity of the associated gene becomes suppressed 
either through direct effects on the gene or as a result of a conformational change of 
the chromatin affecting transcription (Kass, Pruss et al. 1997). CpG island 
méthylation is maintained by a number of DNA methyltransferases (DNMTs). 
Méthylation has been shown to result in loss of ER expression in breast cancer cells, 
while ER positive cells do not demonstrate méthylation of the ER gene (Ottaviano, 
Issa et al. 1994). Subsequent treatment with a DNMT inhibitor 5-aza-2’-cytidine
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resulted in déméthylation of the ER CpG island with re-expression of both ER 
mRNA and protein (Ferguson, Lapidus et al. 1995). In breast tumours, the degree of 
méthylation of the ER gene has been shown to be inversely proportional to ER 
status, with ER positive tumours associated with low levels of méthylation while ER 
negative tumours demonstrated the highest level of méthylation (Lapidus, Nass et al. 
1998).
1.3.3 Signalling through ER
In ER positive tumours, both oestrogens and growth factors can stimulate 
proliferation, invasion as well as the production and secretion of a number of 
proteins, while only growth factors drive these processes in ER negative tumours 
(Lippman, Dickson et al. 1986). ER belongs to a large superfamily of nuclear 
receptors which classically act as ligand-inducible transcription factors (Bjomstrom 
and Sjoberg 2005). When not bound to oestrogen, the receptor is sequestered in a 
multiprotein inhibitory complex as monomers bound to heat shock proteins either 
within the cytoplasm or nucleus of the cell (Jensen 1991). Lipid soluble oestrogens, 
most commonly 17P-estradiol (E2), diffuse across the cell membrane, bind to the 
receptor resulting in dissociation of the receptor from the heat shock proteins 
followed by a series of sequential events. Initially, the binding of E2 to the receptor 
induces phosphorylation of ER at several distinct serine/threonine residues (Le Goff, 
Montano et al. 1994). This results in alteration of its conformation which facilitates 
receptor dimérisation which then form complexes with a number of different co- 
regulatory molecules with subsequent binding to the promoter regions of target 
genes altering gene transcription (Kumar and Chambon 1988; Nilsson, Makela et al. 
2001; Rosenfeld and Glass 2001; Osborne, Shou et al. 2005). The co-regulatory 
proteins function by modulating the transcriptional activity of ER target genes 
(McKenna, Lanz et al. 1999). Co-activators amplify ER-mediated gene transcription 
by altering chromatin structure via their histone acetylase activity (Osborne and 
Schiff 2003). Many of these co-activators, including AIB1 and CBP have been 
identified and studied (figure 1.3).
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Figure 1.3: Binding o f E ? to ER causes receptor dimérisation, binding o f ER to ERE 
with recruitment o f  co-activators resulting in transcription o f the target gene. 
Adapted from Osborne, Shou et al 2005.
Abbreviations: E2 - 17afi-estrdiol; ER - oestrogen receptor; ERE - oestrogen 
response element; AIB1- amplified in breast 1; CBP - cAMP response element 
binding protein; mRNA - messenger ribonucleic acid
In contrast, when selective oestrogen receptor modulators such as tamoxifen bind to 
ER, a different conformational change occurs to the receptor dimer complex which 
facilitates the recruitment of co-repressors such as SMRT and NCoR along with their 
associated histone deacetylases (figure 1.4). These co-repressors inhibit 
transcriptional activity by preventing chromatin unwinding thereby decreasing the 
expression of target genes resulting in reduced cell proliferation (Smith, Nawaz et al. 
1997; Osborne and Schiff 2003; Shou, Massarweh et al. 2004).
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F ig u r e  1 .4 : Tamoxifen binding to ER results in recruitment o f co-repressors to 
receptor complex which inhibits gene transcription. Adaptedfrom Osborne, Shou et 
al 2005.
Abbreviations: ER - oestrogen receptor; ERE - oestrogen response element; OHT - 
4-hydroxytamoxifen; NCoR - nuclear receptor co-repressor; SMRT - silencing 
mediator for retinoid and thyroid-hormone receptor
ER dimers can also indirectly interact with DNA to promote transcriptional activity. 
This occurs through protein-protein interaction with other transcription factors such 
as Fos or Jun, resulting in the recruitment of acetyltransferases to complexes bound 
to activator protein-1 (AP-1) or specificity protein-1 (SP-1) sites on DNA, so-called 
ERE-independent genomic actions (figure 1.5) (Gottlicher, Heck et al. 1998; 
Kushner, Agard et al. 2000). There are also a number of oestrogen target genes 
which lack the ERE but instead contain ERE half-sites which are able to form 
interactions with the orphan nuclear hormone receptor steroidogenic factor-1 (SF-1). 
These are known as SF-1 response elements and serve as direct binding sites for ER 
(O'Lone, Frith et al. 2004).
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Figure 1.5: ER can indirectly promote transcriptional activity through its 
interactions with transcription factors bound to AP-1 or SP-1 sites. Adapted from  
Osborne, Shou et al 2005.
Abbreviations: ER - oestrogen receptor; AIB1- amplified in breast 1; CBP - cAMP 
response element binding protein; mRNA - messenger ribonucleic acid; AP-1 - 
activator protein-1; SP-1 - specificity protein-; mRNA - messenger ribonucleic acid
These three methods of ER induced transcriptional activity represent the genomic 
endocrine pathway, which can also be referred to as the nuclear-initiated steroid 
signalling pathway.
ER has also been shown to signal through another pathway known as the non- 
genomic or membrane-initiated steroid signalling pathway (figure 1 .6 ).Signalling 
through this pathway allows ER functions to occur more rapidly within a cell when 
compared to protein synthesis from gene transcription (Beato 1989). In vitro studies 
have demonstrated the presence of ER located outside the nucleus, both within the 
cell cytoplasm or bound to the plasma membrane (Levin 1999; Razandi, Pedram et 
al. 2003; Shou, Massarweh et al. 2004). Non-genomic signalling can occur when the 
ligand, E2 interacts with the plasma-membrane bound ER (Kousteni, Bellido et al. 
2001). Other functional areas of the receptor can also participate in the signalling 
network through various protein-protein interactions.
ER that is bound to the plasma membrane has been shown to associate with a 
number of transcription factors and signalling molecules including the scaffold 
protein caveolin-1 (Chambliss, Yuhanna et al. 2000; Razandi, Oh et al. 2002), G
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proteins (Razandi, Pedram et al. 1999; Wyckoff, Chambliss et al. 2001), the p85a 
regulatory subunit of phosphatidylinositol-3-OH kinase (PI3K) (Simoncini, Hafezi- 
Moghadam et al. 2000), She (Song, McPherson et al. 2002) and ras (Migliaccio, 
Piccolo et al. 1998). Membrane bound ER can also activate various protein-kinase 
cascades (Losel and Wehling 2003) including HER2/neu signalling (Chung, Sheu et 
al. 2002) as well as MAPK activation through direct interaction with the insulin 
growth factor-1 (IGF-1) receptor (Kahlert, Nuedling et al. 2000). E2 activation of the 
membrane-bound ER can result in interaction with Src kinase through the scaffold 
protein MNAR (modulator of nongenomic action of oestroge receptor) thereby 
increasing Src kinase activity resulting in activation of the MAPK signalling 
pathway (Wong, McNally et al. 2002). ER activation of G proteins with resultant Src 
kinase and matrix metalloproteinase 2  activity cleaves heparin-binding epidermal 
growth factor (EGF) from the cell surface which can then interact with adjacent EGF 
receptors causing increased activity of the MAPK pathway (Razandi, Pedram et al. 
2003). This non-genomic function can result in the mobilisation of intracellular 
calcium (Improta-Brears, Whorton et al. 1999) as well as the stimulation of cAMP 
production and adenylate cyclase activity (Aronica, Kraus et al. 1994; Improta- 
Brears, Whorton et al. 1999; Razandi, Pedram et al. 1999).
Clinically, this non-genomic signalling cascade may contribute to tumour resistance 
to endocrine therapies, in particular selective oestrogen receptor modulators 
(SERMs) in cells with abundant EGFR, HER2 and other cytoplasmic proteins that 
are able to sequester ER within the cytoplasm outside of the nucleus (Kumar, Wang 
et al. 2002; Wong, McNally et al. 2002; Shou, Massarweh et al. 2004).
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Figure 1.6: Activation o f membranous ER can increase signalling through different 
growth factor pathways in turn activating and augmenting nuclear ER functions. 
Adapted from Osborne, Shou et al 2005.
Abbreviations: ER - oestrogen receptor; E2 -17afi-estrdiol hydroxytamoxifen; EGFR 
- epidermal growth factor receptor; PI3K - phosphatidylinositol-3-OH kinase; 
IGF1R - insulin-like growth factor-1 receptor
1.3.4 pS2 -  A classical ER target gene
pS2, also known as trefoil factor 1 (TFF1), is a small cysteine-rich protein of 84 
amino acids (Jakowlew, Breathnach et al. 1984; Ather, Abbas et al. 2004) that is 
secreted by cells as a mature 60 amino acid protein which then undergoes 
dimerisation (Rio, Bellocq et al. 1988; Marchbank, Westley et al. 1998). It is 
expressed in a number of sites including the gastrointestinal tract (Rio, Bellocq et al. 
1988; Piggott, Henry et al. 1991; Poulsom and Wright 1993), prostate (Ather, Abbas 
et al. 2004) and breast epithelium (Piggott, Henry et al. 1991). It is encoded by the 
TFF1 gene (Piggott, Henry et al. 1991) whose expression in breast cancer is 
stimulated in response to oestrogen (Westley, May et al. 1984) with pS2 mRNA 
concentrations increased up to 1 0 0 -fold following oestrogen treatment 
(Masiakowski, Breathnach et al. 1982; May and Westley 1986; May and Westley 
1988). Oestrogen stimulates gene expression through the binding of ER complex to a 
13 base pair ERE which is located 400 bases upstream in the 5’ region of the
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transcription start site (Berry, Nunez et al. 1989; May and Westley 1997). It belongs 
to a family of small secretory proteins which are characterised by three intrachain 
disulphide bonds resulting in a trefoil motif (Reshkin, Tedone et al. 1999). pS2 is the 
most commonly identified target gene of ER which was first isolated from breast 
cancer cells in 1982 in an oestrogen dependent fashion (Masiakowski, Breathnach et 
al. 1982; Prud'homme, Fridlansky et al. 1985; May and Westley 1986; Nunez, 
Jakowlev et al. 1987). Its expression is found predominantly in ER positive breast 
cancer cell lines, with minimal expression found in ER negative cell lines (May and 
Westley 1986; May and Westley 1988; Henry, Nicholson et al. 1990; Carr, May et 
al. 1995). Rio et al also found that most pS2 positive breast tumours were also ER 
positive, suggesting a relationship between ER expression and pS2 production (Rio, 
Bellocq et al. 1987).
pS2 has been extensively studied in both clinical (Henry, Piggott et al. 1991; 
Foekens, van Putten et al. 1993; Gion, Mione et al. 1993) and cell culture studies 
(Nunez, Jakowlev et al. 1987; Nunez, Berry et al. 1989; Miyashita, Hirota et al.
1994; van Agthoven, van Agthoven et al. 1994). It has been shown to be expressed 
predominantly in ER positive tumours (Rio, Bellocq et al. 1987; Henry, Nicholson et 
al. 1990; Henry, Piggott et al. 1991; Soubeyran, Wafflart et al. 1995) with high 
protein levels predictive of a favourable prognosis (Foekens, van Putten et al. 1993; 
Soubeyran, Wafflart et al. 1995) as well as a favourable response to endocrine 
therapy in advanced breast cancer (Henry, Piggott et al. 1991). While pS2 has been 
well established as a target gene of ER and therefore a marker of ER activity, its 
biological function is as yet unknown, with the possibility that it might have a role to 
play as a chemoattractant for breast cancer cells facilitating cellular migration (Prest, 
May et al. 2002).
1.3.5 Anti-oestrogen therapy
At least 70% of breast cancers are classified as being ER positive (Harvey, Clark et 
al. 1999) which has resulted in the development of therapies designed to interfere in 
the action of oestrogen on the ER to reduce cell proliferation and tumour growth.
The link between ovarian function through oestrogen production and secretion and 
the development of breast cancer has been known for over a century (Beatson 1896;
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Boyd 1900). Today, pharmacological therapies have replaced surgical excision of the 
ovaries in the treatment of ER positive breast cancers. There are currently three 
different pharmacological methods of targeting the endocrine pathway: the selective 
oestrogen receptor modulators (SERMs), selective oestrogen receptor 
downregulators (SERDs) and aromatase inhibitors (AIs).
1.3.5.1 Selective oestrogen receptor modulators (SERMs)
SERMs are a class of compounds that structurally resemble oestrogens and act by 
competitively binding with ER. The most widely used and successful SERM to date 
is tamoxifen. Tamoxifen was initially synthesised in the early 1960s during an 
attempt to develop a new contraceptive agent (Harper and Walpole 1966; Harper and 
Walpole 1967). Its potential as an agent to treat and prevent breast cancer took many 
years to be recognised, however now it is the most widely used anti-oestrogen 
therapy. Tamoxifen is a prodrug that is converted to 4-hydroxytamoxifen, an anti- 
oestrogenic metabolite that has a high affinity for ER (figure 1.7) (Jordan, Collins et 
al. 1977; Allen, Clark et al. 1980).
Figure 1 .7: Molecular structures o f tamoxifen, 4-hydroxytamoxifen and raloxifene
The binding of the metabolically active form of tamoxifen to ER results in a 
conformational change to the receptor complex, resulting in its association with co­
repressors and therefore no transcriptional activity (see figure 1.4) (Shang, Hu et al. 
2000). SERMs, including tamoxifen, have both agonistic and antagonistic effects on 
ER depending on the tissue site of the receptor. It has an antagonistic effect in breast 
and mammary tissue (Jordan 1976), with agonistic effects in bone (Jordan, Phelps et
HO
Tamoxifen 4-Hydroxytamoxifen
>n
Raloxifene
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al. 1987). On uterine endometrial tissue it has both agonistic and antagonistic effects 
(Harper and Walpole 1967), with a recognised complication of tamoxifen therapy 
being a 2 to 4 fold increase in the development of endometrial cancer (Fomander, 
Rutqvist et al. 1989; Fisher, Costantino et al. 1994).
In the adjuvant setting, treatment with tamoxifen for five years has been shown to be 
effective in reducing the risk of both invasive breast cancer and ductal carcinoma in 
situ by up to 50% in both pre and post menopausal women (Fisher, Costantino et al. 
1998; Cuzick, Forbes et al. 2002). It has also been shown to reduce the risk of 
contralateral breast cancer (Cuzick and Baum 1985) and can prevent the risk of 
breast cancer development in high risk women (Fisher, Costantino et al. 2005).
The effectiveness of tamoxifen stimulated an interest to develop other SERMs. One 
such drug is raloxifene (figure 1.7), which was developed for the treatment and 
prevention of osteoporosis (Ettinger, Black et al. 1999). When compared with 
tamoxifen in the STAR (Study of Tamoxifen And Raloxifene) trial, raloxifene had 
comparable overall patient survival rates however it was associated with lower rates 
of endometrial cancers and thromboembolic events (Vogel, Costantino et al. 2006).
1.3.5.2 Selective oestrogen receptor downregulators (SERDs)
SERDs such as fulvestrant, a 17a-alkylsulphinyl analogue of E2, are another group 
of anti-oestrogens. They have a high affinity for ER but do not have the same 
agonistic effects as seen with tamoxifen (Addo, Yates et al. 2002), resulting in them 
being termed ‘pure anti-oestrogens’. SERDs function by binding, blocking and 
degrading ER leading to an inhibition of signalling through the ER (Wakeling 1993; 
Wakeling 2000).
Fulvestrant has been shown to be at least as effective as the aromatase inhibitor 
anastrozole as a second line treatment (Robertson, Osborne et al. 2003), while high 
dose fulvestrant has been shown to be superior to anastrozole in improving time to 
disease progression and as effective as anastrozole in improving overall survival 
when used as a first line agent (Robertson, Llombart-Cussac et al. 2009). It has also 
been shown to be as effective as anastrozole in the treatment of ER positive patients
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with metastatic disease refractory to tamoxifen treatment (Howell, Robertson et al. 
2002; Osborne, Pippen et al. 2002).
1.3.5.3 Aromatase inhibitors (AIs)
Aromatase is an enzyme of the cytochrome P-450 superfamily and is a product of the 
CYP19 gene (Evans, Ledesma et al. 1986). It is responsible for the synthesis of 
oestrogens from androgenic substrates, in particular oestrone (El) from 
androstenedione and estradiol (E2) from testosterone. Therefore, aromatase 
inhibitors act to suppress the action of aromatase thereby suppressing plasma 
oestrogen levels. While E2 is the main oestrogen source in premenopausal women,
El is the main source of plasma oestrogen in postmenopausal women (Lonning, 
Haynes et al. 2011). Although El is biologically inactive, the enzymes that are 
required to convert it into active E2 (i.e. sulfatases and reductases) are expressed by 
many tissues (Suzuki, Ishida et al. 2009). Anastrozole and letrozole are third 
generation AIs which function through reversible binding to the heme group of the 
enzyme while exemestane, another third generation Al, irreversibly binds to the 
same site on the aromatase molecule as androstenedione (Smith and Dowsett 2003).
Five year treatment with anastrozole has been shown to improve disease free 
survival and time to recurrence as well as reducing the incidence of contralateral 
breast cancer development in post-menopausal women when compared to tamoxifen 
(Forbes, Cuzick et al. 2008). In a similar patient cohort, letrozole has also resulted in 
more tumour regressions and was associated with a longer time to disease 
progression than tamoxifen (9.4 vs 6.0 months; p=0.0001) (Mouridsen,
Gershanovich et al. 2001). Treatment with tamoxifen for two years with subsequent 
switching to anastrozole for the remaining three years of treatment also improves 
overall survival and reduces the risk of disease recurrence when compared to 
tamoxifen monotherapy for five years (Kaufmann, Jonat et al. 2007).
Trials are currently ongoing to evaluate the efficacy of third generation AIs in the 
neoadjuvant setting as well as in the prevention of breast cancer development in high 
risk women.
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1.4 Hum an epidermal growth fac to r signalling pathways
1.4.1 Epidermal growth factor receptors
Human epidermal growth factor receptors (EGFR), also known as epidermal growth 
factor receptors (ErbB) are transmembrane tyrosine kinase receptors that are 
involved in the regulation of cell growth and differentiation as well as adhesion, 
migration and other responses (Yarden 2001). To date, four separate receptors have 
been identified within the growth factor receptor family: EGFR (HERl/ErbBl), 
HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) (Yarden and Sliwkowski 2001). 
They comprise an extracellular binding domain, a transmembrane lipophilic segment 
and, except for HER3, a functional intracellular tyrosine kinase domain with a 
regulatory carboxyl terminal segment (Mendelsohn and Baselga 2003). Ligand 
binding to the extracellular domain activates the cytoplasmic catalytic function 
through receptor homo or heterodimerisation and self-phosphorylation of the 
intracellular tyrosine residues (Yarden and Sliwkowski 2001). Receptor activation 
results in a signal-transduction cascade promoting responses such as cellular 
proliferation and survival (figure 1.8). While each receptor differs slightly from each 
other, they have structural homology of 40-45% (Plowman, Culouscou et al. 1993). 
HER2 is over-expressed in up to 30% of breast cancers (Slamon, Clark et al. 1987). 
It has been implicated in cancer progression (Yarden 2001) and also can be used to 
predict breast cancer outcome (Winston, Ramanaryanan et al. 2004).
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Figure 1.8: Signalling through the epidermal growth factor receptors results in 
activation o f a number o f intracellular pathways that regulate key cellular 
responses. Adapted from Hudis 2007.
Abbreviations: Akt - protein kinase B; EGF - epidermal growth factor; EGFR - 
epidermal growth factor receptor; FKHR - forkhead homolog 1 rhabdomyosarcoma; 
Grb2 - growth factor receptor-bound protein 2; GSK3 - glycogen synthase kinase 3; 
HER2 - human epidermal growth factor receptor 2; MAPK - mitogen-activated 
protein kinase; mTOR - mammalian target o f rapamycin; PI3K - 
phosphatidylinositol-3-OH kinase; PTEN - phosphatase and tensin homolog; R af - 
rapidly accelerated fibrosarcoma; Ras - RAt sarcoma; Sos - son o f  sevenless
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1.4.2 HER2
HER2 is a 185kDa transmembrane glycoprotein receptor, encoded on chromosome 
17q21, that was first described over two decades ago (Schechter, Stem et al. 1984; 
Coussens, Yang-Feng et al. 1985). Signalling via HER2 occurs through the Ras- 
MAPK pathway to promote cell proliferation and through the phosphatidylinositol 
3’-kinase-AKT-mammalian target of rapamycin (mTOR) pathway to inhibit cell 
death (Cho, Mason et al. 2003). While the other HER receptors interact with ligands 
prior to dimerisation, no natural ligand has yet been identified for HER2 (Chang
2007), instead it can adopt a conformation which resembles a ligand-activated state 
which allows it to dimerise in the absence of a ligand (Cho, Mason et al. 2003). The 
other HER receptors preferentially form heterodimers with HER2, which produce 
more prolonged and stronger signals when compared to non-HER2 containing 
dimers (Chang 2007). Therefore, over-expression of HER2 in certain cell types can 
increase its sensitivity to growth factors resulting in uncontrolled cell proliferation 
leading to tumour growth (Rubin and Yarden 2001).
Over-expression of HER2 has been described in a number of different malignancies, 
however amplification of the HER2 gene is rare except for in breast cancer (Slamon, 
Godolphin et al. 1989; Onda, Matsuda et al. 1996; Latif, Watters et al. 2002). HER2 
over-expression occurs in 20-30% of breast cancers (Slamon, Clark et al. 1987; 
Rubin and Yarden 2001; Hudis 2007). Over-expression in breast cancer is associated 
with decreased overall and disease free survival as well as varying responses to 
different chemotherapeutic and hormonal therapies (Albanell, Bellmunt et al. 1996; 
Ellis, Coop et al. 2001; Menard, Valagussa et al. 2001). In particular, HER2 
amplification is associated with the development of resistance to tamoxifen 
(Osborne, Bardou et al. 2003; Shou, Massarweh et al. 2004).
1.4.3 Trastuzumab
In view of the important prognostic implications of HER2 over-expression in breast 
cancer, research has focused on developing new therapies which successfully inhibit 
the HER2 receptor and its signalling pathway. This has resulted in the development 
of biological agents targeted against the erbB family of tyrosine kinase receptors.
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Trastuzumab (Herceptin®, Genentech/Roche) is a monoclonal antibody that was 
engineered by inserting the antigen-binding residues from a murine monoclonal 
antibody against the receptor into a cloned human immunoglobulin G framework 
(Carter, Presta et al. 1992). Its complementary-determining region amino acids bind 
to amino acids present on domain IV of the HER2 ectoderm (Cho, Mason et al. 
2003). Its exact mechanism of action in vivo is unclear, but is thought to be divided 
into those mediated by Fab (fragment, antigen binding) or Fc (fragment, 
crystallisable) resulting in disruption of cell cycle progression and downstream 
proliferative signalling pathways (Albanell, Codony et al. 2003) as well as antibody- 
dependent cellular cytotoxicity (Cooley, Bums et al. 1999) and antiangiogenic 
effects (Izumi, Xu et al. 2002).
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Figure 1.9: Proposed mechanism o f  action o f  trastuzumab. Adapted from Hudis 
2007.
Following preclinical testing as well as a number of phase II clinical trials, in 1998 
the US Food and Drug Administration (FDA) approved the use of trastuzumab for 
the treatment of HER2 positive patients with metastatic breast cancer. In 2001, a 
landmark phase III clinical trial revealed the benefits of combining trastuzumab with 
chemotherapy in patients with metastatic disease, improving both time to disease 
progression as well as overall survival rates (Slamon, Leyland-Jones et al. 2001).
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Subsequent trials have revealed its benefits in both the adjuvant (Piccart-Gebhart, 
Procter et al. 2005; Romond, Perez et al. 2005) and neoadjuvant setting (Gianni, 
Eiennann et al. 2010).
While myelosuppression, nausea and alopecia is rare with trastuzumab monotherapy, 
combination therapy with an anthracycline chemotherapeutic agent when compared 
to anthracycline chemotherapy alone was found to increase the rate of cardiac 
dysfunction from 8 % to 27% (Slamon, Leyland-Jones et al. 2001). While the 
underlying mechanism of cardiotoxicity is poorly understood, HER2 has been linked 
with embryonic cardiac development as well as the prevention of dilated 
cardiomyopathy (Negro, Brar et al. 2004). Accordingly, concurrent use of 
trastuzumab with anthracycline-based chemotherapy regimes is not advised with 
interval monitoring of cardiac function for patients receiving trastuzumab treatment.
1.5 Resistance to treatments
1.5.1 Tamoxifen resistance
Without question tamoxifen has revolutionised the treatment of ER positive breast 
cancers. Adjuvant tamoxifen therapy prolongs disease-free and overall survival in 
primary breast cancers which express ER, as well as reducing the annual risk of 
recurrence by up to 50% (Group 1992). It has also been shown to induce a clinical 
response in more than half of patients with ER positive cancers who present with 
metastatic disease (Osborne 1998). However, the Early Breast Cancer Trialists’ 
Collaborative Group meta-analysis looking at tamoxifen treatment for five years in 
ER positive cancers found a recurrence rate of 15.1% at five years which increased 
to 24.7% at ten years post diagnosis (Group 1992). Furthermore, metastatic disease 
which initially responds to tamoxifen therapy will always develop resistance to the 
drug (Kurebayashi 2005). This would suggest that up to half of ER expressing 
cancers have a de novo resistance to tamoxifen with a significant proportion of 
responsive tumours acquiring resistance during treatment. De novo resistance occurs 
mainly through two mechanisms: lack of ER expression (i.e. ER negative tumours) 
or variant expression of the cytochrome P450 isoenzyme CYP2D6 resulting in the
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inability to metabolise tamoxifen to its metabolically active form, 4 
hydroxytamoxifen (4-OHT). There are many genetic variants of CYP2D6 which are 
broadly categorised into four distinct phenotypes: ultra rapid (high activity), 
extensive (normal activity), intermediate (reduced activity) and poor (no activity). 
Patients with two functional CYP2D6 allelles (i.e. extensive phenotype) have been 
shown to have better outcomes, while patients with non-functional (poor phenotype) 
or reduced activity (intermediate phenotype) have worse outcomes (Schroth, Goetz 
et al. 2009).
In acquired resistance, tumours initially respond to tamoxifen however, after a 
period of time, they re-occur and grow despite continued tamoxifen treatment, 
thereby demonstrating resistance to the medication. Extensive research has been 
undertaken to determine the mechanisms by which cancers develop resistance to 
tamoxifen, with a number of possibilities proposed. In general, acquired resistance is 
not a result of loss of or alteration to ER, with less than 20% of recurrences found to 
lose expression of ER (Kuukasjarvi, Kononen et al. 1996; Broom, Tang et al. 2009). 
Cancers which are resistant to tamoxifen frequently respond to other forms of anti­
oestrogen therapies such as fulvestrant or aromatase inhibitors confirming that 
tumour development and progression is still influenced by signalling through the 
endocrine pathway (Howell, DeFriend et al. 1996).
One method by which tumours are thought to develop resistance to tamoxifen is 
through crosstalk between ER and the growth factor receptor pathways including the 
EGFR/HER2 family of receptors. This can result in the development of resistance 
through a number of differed mechanisms. Cell-membrane associated ER is a G 
protein coupled receptor, whose subunits have been shown to activate EGFR. The 
exact mechanism by which ER within the cell membrane activates this growth factor 
receptor pathway is unclear, however it is thought to involve Src kinase activation of 
the metalloproteinases, in particular MMP-2 and MMP-9, which subsequently 
induce the secretion of heparin bound epidermal growth factor thereby 
transactivating EGFR (Razandi, Pedram et al. 2003). This results in activation of the 
MAPK pathway followed by phosphorylation of extra-cellular signal-related kinase 
1 (ERK1) and ERK2 (Razandi, Pedram et al. 2003; Shou, Massarweh et al. 2004).
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Signalling through the growth factor receptor pathway consists of a protein kinase 
cascade as demonstrated in figure 1.8. Activation of the phosphatidylinositol 3- 
kinases (PI3K) pathway results in upregulation of Akt, which subsequently 
phosphorylates ER at serine 167 thereby enhancing its transcriptional activity 
(Campbell, Bhat-Nakshatri et al. 2001). Upregulation of ras results in the activation 
o f various signalling intermediates which in turn phosphorylate and activate MAPK 
and subsequently ERK1 and ERK2. ERKs can then activate ER through a number of 
different mechanisms including phosphorylation of serine 118 (Kato, Endoh et al.
1995), phosphorylation of p90 ribosomal S6  kinase (P90RSK) (Joel, Smith et al. 
1998) as well as phosphorylation of ER co-activators such as AIB1 (Font de Mora 
and Brown 2000). P38 MAPK can phosphorylate both ER and its co-activators 
thereby augmenting ER-mediated gene transcriptional activity (Lee and Bai 2002). 
Indeed, preclinical studies have confirmed that tamoxifen resistance is associated 
with increased levels of different kinases (Schiff, Reddy et al. 2000).
The nuclear receptor co-activators play an integral role in the mediation of ER 
transcription, therefore alterations in the expression of these co-regulator proteins 
may result in tamoxifen resistance. Over-expression of nuclear co-activator 3 (also 
known as AIB1) has been associated with reduced disease free survival in patients 
who are receiving adjuvant tamoxifen therapy (Osborne, Bardou et al. 2003). The 
paired domain transcription factor PAX2 has been shown to be a direct competitor 
with AIB1 for binding and regulation of ERB2 transcription (Hurtado, Holmes et al.
2008). In vitro studies revealed recruitment of PAX2 to an ER binding site within the 
ERB2 gene following treatment with both oestrogen and tamoxifen with evidence 
suggesting a role for PAX2 as a transcriptional repressor of ER. Subsequent 
translational studies comparing the relevance of PAX2 within the clinical setting 
found that out of a cohort of 109 patients with ER positive breast cancers, those 
patients who expressed PAX2 had a significantly improved recurrence-free survival. 
In vitro studies have also shown that overexpression of SRC 1, a p 160 nuclear 
receptor co-activator can result in the enhanced agonist activity of 4-hydroxy- 
tamoxifen (Smith, Nawaz et al. 1997). SRC-1 has also been shown to interact with 
the developmental transcription factor HOXC11 leading to the development of 
tamoxifen resistance through their regulation of the calcium-binding protein 
SlOObeta (Mcllroy, McCartan et al. 2010).
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1.5.2 Trastuzumab resistance
Development of resistance to trastuzumab is increasingly becoming an important 
clinical issue. While quantification of HER2 expression can identify patients who are 
likely to respond to trastuzumab treatment, a proportion of patients who receive 
adjuvant trastuzumab-containing therapy will relapse. Moreover, less than one third 
of patients with metastatic breast cancer who over-express HER2 will have an 
objective response to trastuzumab monotherapy and the majority of patients who do 
have an initial response develop resistance within one year. The exact mechanisms 
by which resistance develops remain inconclusive, with hypothesised mechanisms 
described in preclinical models but not yet validated in clinical samples. The 
proposed main mechanisms include alteration in the interaction between the receptor 
and the antibody, alternative signalling through other HER pathways or alternate 
pathways or failure to activate immune-mediated mechanisms to destroy tumour 
cells (figure 1.10) (Fiszman and Jasnis 2011). Determining which of these 
mechanisms is clinically relevant is an important goal of research, with it likely that, 
as with tamoxifen, clinical resistance occurring as the result of a multifactorial 
process.
(c> Increased ngnuUtig 
from other itc q n o n
(u) Impaired immune-medialiod mcclliinlscm(a) Epnopc masking to) Truikcatrd IIER2
(b) F T E N  loss
Alter n il i ve 
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eignaling
(c) Increased signaling 
from HER faniSy rteefHUmt
(b ) P D K I dnage*
Figure 1.10: Proposed mechanisms for trastuzumab resistance. Adapted from 
Fiszman and Jasnis 2011.
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The membrane-associated glycoprotein mucin-4 (MUC4) has been shown to interact 
directly with HER2, which is postulated to mask the receptor thereby preventing 
trastuzumab from effectively interacting with it (Price-Schiavi, Jepson et al. 2002). 
Preclinical studies have shown that the MUC4 protein level correlates with 
resistance to trastuzumab as well as being inversely proportional to the binding 
capacity of HER2 for the antibody (Nagy, Friedlander et al. 2005). Alteration in the 
interaction between the receptor and the antibody can also occur following cleavage 
of the extracellular domain of HER2 by proteases resulting in a truncated form of the 
receptor, known as p95HER2, to which trastuzumab is unable to bind (Molina, Saez 
et al. 2002). This truncated form of HER2 is constitutively active and therefore can 
mediate trastuzumab resistance (Scaltriti, Rojo et al. 2007).
Crosstalk is known to occur among the different receptors of the HER family, 
therefore, while trastuzumab can reduce signalling through HER2 it might not affect 
signalling through the other receptors. Thus, even in the presence of trastuzumab, 
HER1/HER3 heterodimers and HER1/HER1 homodimers might initiate signalling 
through the MAPK and PI3K pathways (Motoyama, Hynes et al. 2002). In vitro 
models examining the effect of increased levels of the HER family ligands heregulin 
and epidermal growth factor (EGF) showed inhibition of the trastuzumab-mediated 
growth reduction in HER2 overexpressing breast cancer cell lines (Robinson, Turbin 
et al. 2006). Likewise, transforming growth factor-p (TGF-P), through its action on 
HER3 ligand shedding, has been shown to have a role in the development of 
resistance to anti-HER2 therapies (Wang, Xiang et al. 2008). Increased levels of 
insulin-like growth factor-1 receptor (IGF-1R) in HER2 overexpressing breast 
cancer cell lines appear to affect the efficacy of trastuzumab resulting in the 
development of resistance, with inhibition of IGF-1R signalling restoring the 
sensitivity of cells to the agent (Casa, Dearth et al. 2008). It is thought that IGF-1R 
induced trastuzumab resistance involves the PI3K signalling pathway resulting in 
enhanced degradation of p27 (Lu, Zi et al. 2004). Co-expression of IGF-1R in 
operable FEER2 overexpressing breast tumours treated with neoadjuvant trastuzumab 
in conjunction with vinorelbine was associated with significantly lower response 
rates (50% versus 97%, p=0.001) when compared to tumours which did not co­
express IGF-1R (Harris, You et al. 2007). Antibody-dependent cellular cytotoxicity 
(ADCC) is thought to be significantly involved in the functional activity of
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trastuzumab, with interactions between the antibody and the Fc receptor critical in 
the activation of natural killer lymphocytes and the ADCC response. Preclinical 
studies suggest that germline polymorphisms as well as post-translational 
modifications such as glycosylation of the Fc receptor result in a reduction of the 
ADCC response to trastuzumab, thereby impairing the immune-mediated ability to 
destroy tumour cells.
1.6 Hypothesis
Recent research has highlighted the complex nature of the signalling pathways 
within breast cancer cells. Crosstalk between the main two pathways, the steroid 
hormone and growth factor pathways, has already been implicated in the 
development of resistance to anti-oestrogen therapies such as tamoxifen. We 
hypothesise that resistance to trastuzumab, as well as other tyrosine kinase inhibitors, 
can, in part, be mediated by crosstalk between the growth factor signalling pathway 
and the steroid hormone pathway that results in an uncontrolled upregulation of the 
steroid hormone pathway following trastuzumab treatment.
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AFigure 1.11: Schematic representation o f overall hypothesis.
(a): Steroid hormone and growth factor pathways play an integral role in tumour 
growth (b): We hypothesise that growth factor pathway inhibition by trastuzumab 
results in upregulation o f the steroid hormone pathway
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1.7 Aims
The overall aim of this work is to further elucidate the interactions between the 
steroid hormone and growth factor signalling pathways in breast cancer, in 
particular, to determine the effect of trastuzumab treatment on the steroid hormone 
pathway. The first objective will be to assess the effect of trastuzumab treatment on 
this pathway at a molecular level in breast cancer cells, looking at its effect at both a 
protein level and a transcriptional level. Secondly, we will verify our in vitro 
findings in breast cancer tissue samples utilising a large tissue microarray, assessing 
the clinical significance of our proposed crosstalk hypothesis.
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C h a p t e r  2
Materials and Methods
2 .1 Breast cancer cell culture techniques
2.1.1 MCF-7 breast cancer cell line
MCF-7 cells, a well established breast cancer cell line which overexpress ER and PR 
but not HER2 were obtained from the American Type Culture Collection (ATCC, 
Virginia, USA). They were cultured in minimum essential medium (MEM) (Sigma 
Aldrich, Stenheim, Germany) supplemented with 10% foetal calf serum (FCS) 
(Sigma Aldrich), 10,000 units of penicillin (Sigma Aldrich), lOmg of streptomycin 
(Sigma Aldrich) and 1ml of 200mM L-glutamine (Sigma Aldrich) per lOOmls of 
medium.
2.1.2 LCC-1 breast cancer cell line
LCC-1 cells are an isogenic derivative of MCF-7 cells which overexpress both ER 
and HER2. Although they express ER, they are independent of oestrogen however 
they retain sensitivity to the effects of anti-oestrogen therapies such as tamoxifen 
(Brunner, Boulay et al. 1993). They were a kind gift from Dr. Robert Clarke, 
Department of Oncology, Georgetown University, USA. Phenol red is a weak 
oestrogen mimic, therefore to maintain their oestrogen independence, they were 
cultured in phenol red free MEM supplemented with 10% charcoal dextran stripped 
foetal calf serum (Sigma Aldrich), 10,000 units of penicillin (Sigma Aldrich), lOmg 
of streptomycin (Sigma Aldrich) and 1ml of 200mM L-glutamine (Sigma Aldrich) 
per lOOmls of medium. Charcoal dextran stripping reduces the scrum concentration 
of a number of different hormones as well as certain growth factors including 
cortisol and prostaglandins.
2.1.3 SKBR-3 breast cancer cell line
SKBR-3 cells carry multiple copies of the c-erbB2 gene resulting in overexpression 
of HER2; however they do not express ER. Cells were obtained from the ATCC and 
cultured in RPMI 1640 medium (Sigma Aldrich) supplemented with 10% foetal calf
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serum (FCS), 10,000 units of penicillin and 1 Omg of streptomycin per lOOmls of 
medium.
2.1.4 Culturing of cells from cryo-storage
Cryovials containing cells were removed from storage in liquid nitrogen and thawed 
quickly. The contents of the cryovial were transferred to a sterile 15mls conical tube 
(Greiner Bio-One, Frickenhausen, Germany) containing 5mls of the appropriate 
culture medium. The cell suspension was centrifuged at 1,250 rpm for 4 minutes, the 
supernatant was discarded and the cell pellet resuspended in 2mls of medium. Cells 
were then transferred to a 75cm2 tissue culture flask (Sarstedt, Niimbrecht, Germany) 
to which a further 8 mls of medium was added. The flasks were then incubated at 
37°C.
2.1.5 Cell culture
All cell culture techniques were performed under sterile conditions using a laminar 
airflow cabinet. Cells were maintained in 75cm2 tissue culture flasks in a Heraeus 
Hera Cell incubator (Kendro Laboratory Products, Hanau, Germany) at 37°C with a 
humid 5% (v/v) CO2 atmosphere. Cells were passaged when confluent. Following 
washing in PBS (PBS, Oxoid Ltd, Hampshire, England) cells were incubated in 2mls 
of lx  trypsin/EDTA solution (Sigma Aldrich) containing 0.05% trypsin and 0.02% 
EDTA for 5 minutes at 37°C. Trypsin was inactivated by the addition of full growth 
medium and transferred to a 15mls conical tube which was then centrifuged at 
l,250rpm for 4 minutes. The supernatant was discarded and the cell pellet was 
resuspended in the required amount of medium which was then divided into fresh 
tissue culture flasks. Cells were routinely tested for mycoplasma every 4 to 6  months 
(MycoAlert mycoplasma detection kit, Lonza, Basel, Switzerland) to ensure that 
contamination of the cell lines did not occur.
2.1.6 Cell counting
Prior to seeding cells in cell culture well-plates, cells must be counted to ensure that 
they attain adequate confluency within their wells, without becoming over or under
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confluent. This is achieved using a haemocytometer to count cells in suspension. 
After trypsinisation and formation of a cell pellet as described in 2.1.5, the cell pellet 
was resuspended in 5mls of medium and mixed by vortex to ensure an even 
distribution of cells within the suspension. A 50(4.1 sample of this solution was mixed
with 50(xl of trypan blue (Sigma Aldrich). lOjal of this mixture was placed onto the
• « ■ 2 haemocytometer with the number of healthy cells present within the central 1 mm
grid counted. Apoptotic cells were recognisable by weakened cell membranes that
allowed the trypan blue to penetrate into the cell and were not counted. This process
was repeated three times with the average value multiplied by both the dilution
factor and 10,000 to calculate the number of cells per millilitre. This was then used
to determine the required volume of cell suspension which was then seeded into the
relevant cell culture well-plate.
2.1.7 Cell treatments
Prior to treatment, culture medium was removed from the flasks and cells were 
washed twice in sterile PBS. MCF-7 and SKBR-3 cells were then cultured for 48 
hours in phenol red free MEM containing 10% charcoal dextran stripped foetal calf 
serum, followed by an additional 24 hours in serum free MEM. LCC-1 cells were 
washed twice in sterile PBS and cultured for 24 hours in serum free MEM. All cells 
were then treated with 17(3-estradiol (E2) (Sigma Aldrich) at 10‘8M concentration, 4- 
hydroxytamoxifen (4-OHT) (Sigma Aldrich) at 10"8M concentration and trastuzumab 
(kind gift from pharmacy department, Beaumont Hospital) at 100pM/ml 
concentration. Sterile water was used as a vehicle control.
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2.2 Western b lot analysis
2.2.1 Protein lysate extraction
Western blotting is a technique employed to detect proteins in cell lysates. Protein 
lysate extractions were performed on ice. 1 Ojo.1 of protease inhibitor (P8340, Sigma 
Aldrich) was added to 1ml of radioimmunoprecipitation assay (RIPA) lysis buffer. 
Cell pellets were harvested by centrifugation at 1850 rpm for 7 minutes, the medium 
was removed and the cell pellets were resuspended in 80jo.l of the protease 
inhibitor/lysis buffer mixture. The samples were placed on ice for 10 minutes 
followed by a 30 second vortex, which was repeated a further two times. The 
samples were then centrifuged at 4°C at 13,000rpm for 20 minutes after which the 
supernatant was transferred to a chilled, labelled eppendorf and stored at -20°C for 
further use.
2.2.2 Protein quantification
Protein quantification was performed using a bicinchonic acid (BCA) assay (P23225, 
Pierce, II, USA), as per manufacturer’s instructions. A standard curve was created by 
serially diluting bovine serum albumin in dH20 (Appendix I).
A 1:20 dilution of lysate was made in dH20, ensuring the solution was well mixed. 
25pl of each standard was pipetted into a 96 well plate in duplicate. 25 pi of each 
sample was also pipetted into the 96 well plate in duplicate. The BCA working 
reagent was made up by mixing 1 part of BCA Reagent B (4% w/v CuSCU) with 49 
parts of BCA Reagent A (containing Na2C0 3 , NaHCC>3, BCA detection reagent and 
sodium tartrate in 0.5M NaOH). 200p.l of the working reagent was then added to 
each well containing either a standard or sample. The plate was incubated at 37°C for 
30 minutes after which the absorbance was read at 560nm using a plate reader (KC4, 
BioTek, VT, USA). The average absorbance value for each sample was calculated. 
Linear regression analysis was performed to determine the equation of the standard 
curve which was then used to calculate the protein concentrations of each sample.
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2.2.3 Sodium dodecyl sulphate polyacrylamide gel electorphoresis (SDS- 
PAGE)
Electrophoresis is one of the methods used to separate proteins according to 
molecular weight or charge. Sodium dodecyl sulphate (SDS) is a detergent which 
gives the protein samples a negative charge by wrapping around the polypeptide 
backbone, thereby conferring a negative charge in proportion to the length of the 
polypeptide. This enables the relevant antibody to subsequently gain access to the 
epiptope of interest and also ensures that in SDS-PAGE, the protein separation is 
determined by molecular weight.
Polyacrylamide gels are formed by the polymerisation of acrylamide (Sigma 
Aldrich) and N,N-methylene-bis-acrylamide. The addition of ammonium persulphate 
(APS) (Sigma Aldrich) as well as N,N,N,N-tetramethylethylenediamine (TEMED) 
(Sigma Aldrich) initiates the polymerisation. APS determines the size of the pores 
within the gel, the higher the concentration of APS the smaller the pore size. Pore 
size is varied depending on the size of the protein of interest to ensure adequate 
separation of proteins occurs.
Gels were cast using the ATTO gel system (ATTO Corporation, Tokyo, Japan) and 
allowed to polymerise for 35 minutes at room temperature, with a small layer of 
isopropanol (Sigma Aldrich) on top to ensure the gel set evenly. Once set, the 
isopropanol was removed and a 5% stacking gel was poured on top of the gel. A 10- 
well, 1.5mm comb was inserted into the stacking gel which was then left for 35 
minutes at room temperature to polymerise. The function of the stacking gel is to 
ensure that all the samples begin travelling down the polyacrylamide gel at the same 
time. The composition of the various gels is outlined in table 2.2. A 10% resolving 
gel was used when blotting for ER. Gels were then placed in the ATTO tank which 
was filled with lx  running buffer (Appendix I).
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Table 2.1 Composition o f various percentage gels fo r SDS-PAGE
6%
Resolving
8%
Resolving
10%
Resolving
12%
Resolving
5%
Stacking
H20 5.3 4.6 4.0 3.3 1.4
30% acrylamide mix 2 . 0 2.7 3.3 4.0 0.33
1.5M Tris (pH 8.80) 2.5 2.5 2.5 2.5 0.25
10% SDS 0 . 1 0 . 1 0 . 1 0 . 1 0 . 0 2
10% APS 0 . 1 0 . 1 0 . 1 0 . 1 0 . 0 2
TEMED 0.008 0.006 0.004 0 . 0 0 2 0 . 0 0 2
Each volume is in millilitres and used in the preparation of lOmls of resolving gel 
and 2 mls of stacking gel.
2.2.4 Loading, running and transferring samples
For all western blot experiments, 80(ag of protein was added to 6 x laemelli SDS 
buffer (Sigma Aldrich) as well as varying amounts of protease inhibitor/lysis buffer 
mixture (as described in 2.2.1) so that each sample volume was equal to 25|j.l. This 
was then vortexed briefly and boiled at 95°C for 5 minutes to denature the protein 
samples. 20jxl of each sample was then loaded carefully in to the relevant well. A 
molecular weight marker, Precision plus protein standard (Bio-Rad, CA, USA), was 
run alongside the samples to allow for determination of molecular weight. Gels were 
run at a constant voltage of 110V for 3.5 hours.
After SDS-PAGE electrophoresis, gels were transferred on to a nitrocellulose 
membrane using an ATTO semi-dry transfer system (ATTO Corporation). A 
constant current of 250mA was used with a transfer time of 1 hour. Protein transfer 
was confirmed by rinsing the nitrocellulose membrane with Ponceau S solution 
(Sigma Aldrich).
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2.2.5 Western b lo tting
Non-specific protein binding sites were blocked by placing the nitrocellulose 
membrane in 5% non-fat dry milk (Chivers, Dublin, Ireland) in tris-buffered saline 
(TBS) containing 0.1% Tween (TBST) (Sigma Aldrich) overnight at 4°C. The 
primary antibody was diluted in 2% non-fat dry milk in TBST to a volume suitable 
for the membrane size to the required concentration as documented in table 2.3. 
Membranes were incubated in primary antibody with gentle rocking for one hour at 
room temperature when blotting for ER and overnight at 4°C when blotting for P- 
actin. The membrane was then washed three times for 10 minutes each in TBST. It 
was then incubated for 1 hour at room temperature with the relevant Horseradish 
Peroxidase (HRP) conjugated secondary antibody (Sigma Aldrich) at concentrations 
outlined in table 2.3. The membrane was again washed three times for 10 minutes 
each in TBST before being developed with the Enhanced Chemiluminescence (ECL) 
(Pierce) substrate solution. Light emitted during the enzyme-catalysed 
decomposition reaction was captured by exposure to Fuji X-ray film (FujiFilm, 
Tokyo, Japan) for 30 seconds to 40 minutes. The film was developed by immersion 
in developing solution followed by fixer solution (Kodak, USA) and left to air dry. 
The size of the visualised bands was determined using the molecular weight markers.
Table 2.2 Western blot antibody concentrations
Protein Primary antibody Secondary antibody Chemiluminescent
reagent
ER Santa Cruz Anti-rabbit ECL x 1 minute
6 6 kDa Anti-ER (SC-543) 
1 : 2 0 0  in 2 % milk
1:2000 in 5% milk
P-actin Anti-p-actin Anti-mouse ECL x 1 minute
42kDa 1:7500 in 5% milk 1:7500 in 5% milk
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2.3 Prom oter activ ity  assay
2.3.1 Luciferase assay
Eukaryotic gene expression and cellular physiology can be studied using genetic 
reporter systems. In the luciferase reaction, when the luciferase acts upon the 
appropriate substrate, light is emitted which can be detected and measured by a 
luminometer thereby allowing for the evaluation of biological processes. Luciferase 
assay is commonly used to assay the transcriptional activity of DNA sequences 
which have been transfected with a genetic construct containing the luciferase gene 
that is regulated by the promoter of interest. The simultaneous expression and 
measurement of two individual reporter enzymes within a single system is known as 
a dual reporter system. A dual reporter system allows for the experimental reporter to 
assay the effect of an experimental condition while the co-transfected control 
reporter provides an internal control that can measure the baseline cellular response. 
The activity of the experimental reporter than then be normalised against the internal 
control thereby minimising the experimental variability that can occur within cells.
The Dual Luciferase Reporter (DLR) Assay System (Promega, WN, USA) utilises 
the activity of the firefly (Photinum pyralis) and Renilla (Renilla reniformis) 
luciferases to determine cellular transcriptional activity. Luciferase Assay Reagent II 
(LARII) (Promega) is added initially to measure the firefly luciferase reporter. After 
this is recorded, the reaction is quenched by adding Stop & Glo Reagent (Promega) 
to the sample which simultaneously initiates the Renilla luciferase reaction. Renilla 
activity is measured and used as the internal control to normalise the experimental 
reporter measurement.
2.3.2 ER expression vector and pS2 promoter
The ER-HEGO/pSG5 expression vector was a kind gift from Professor Pierre 
Chambon, University of Strasbourg, France. The control vector was created by 
restricton digest of the ER sequence from the HEGO vector and religating the ends.
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The pGL3-pS2 promoter was a kind gift from Dr Kumar and colleagues at MD 
Anderson Cancer Centre, Texas, USA.
2.3.3 Cellular transfection
Cells were cultured in 24-well plates until they reached 90% confluency. 
Transfections were performed using Lipofectamine™ 2000 (Invitrogen) according to 
manufacturer’s instructions. For each transfection sample, 12.5ng of Renilla 
(Invitrogen, CA, USA) and 500ng of each relevant plasmid and vector (table 2.4) 
was diluted in Opti-MEM reduced serum medium (Invitrogen) to a total volume of 
50(il. 2 pi of Lipofectamine™ 2000 was diluted in 48(4.1 of Opti-MEM and incubated 
for 5 minutes at room temperature. The diluted Lipofectamine™ 2000 was combined 
with the diluted plasmid and vector sample and incubated at room temperature for 2 0  
minutes. Each complex was added to wells containing cells along with 500pl of 
Opti-MEM and incubated for 6  hours at 37°C and 5% CO2 . The Opti-MEM was then 
removed and cells were incubated in fresh media for 16 hours. Cells were then 
treated with E2 and trastuzumab as per section 2.1.7 for 6  hours.
Table 2.3 DNA transfection protocol
DNA(ng) DNA (ng)
Renilla 12.5 12.5
pS2/PGL3 500 500
ER/pSG5 500 0
Empty pSG5 0 500
2.3.4 Luciferase assay protocol
Following transfection, the media was removed from the wells and the cells were 
washed with PBS. Luciferase assay was performed according to manufacturer’s 
instructions (Promega). Cells were lysed by adding 10 0 (4,1 of IX passive lysis buffer 
(Promega) to the wells and placing the plates on a rocker for 15 minutes at room 
temperature. The cell lysates were transferred to eppendorfs and 10(xl of each was
38
mixed with 50(.il of LAR II. Firefly luciferase activity was recorded using a 
luminometer programmed to perform a two second pre-measurement delay followed 
by a ten second measurement period for each assay. Subsequently 50pl of Stop & 
Glo reagent was added to quench the firefly activity and initiate the Renilla 
luciferase activity which was similarly measured using the luminometer. Readings 
were entered onto a Microsoft Excel spreadsheet (Microsoft, WA, USA) with the 
firefly luciferase activity normalised to control Renilla luciferase activity. Results 
were graphed on bar charts. All luciferase experiments were performed in triplicate 
with the average reading used to obtain the final result. Each experiment was 
repeated a further two times to determine the standard error.
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2.4 Nucleic acid biochemistry
2.4.1 RNA extraction
Cells were cultured in 6 -well plates until they reached 90% confluency. They were 
then treated as described in section 2.1.7 for 6  hours after which time RNA 
extraction was performed using the RNeasy Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. lOpl P-mercaptoethanol was added to 1ml 
of Buffer RLT before use. To each cell monolayer 350|o,l of Buffer RLT was added, 
the cells were then scraped off the plate using a pipette tip and the lysate was 
transferred to an eppendorf. Each lysate was homogenised by passing it through a 
20-guage syringe fitted to a 2.5ml RNase-free syringe. 350|_il of 70% ethanol was 
then added to each lysate and pipette mixed, the sample was transferred to an 
RNeasy spin column and centrifuged for 15 seconds at 10,000rpm. The flow through 
was discarded and the membrane was then washed with 700^1 of Buffer RW1 
followed by two washes with 500pl of Buffer RPE, each time centrifuged at 
10,000rpm for 15 seconds. A further 2 minute centrifuge at 15,000rpm was 
performed to dry the spin column membrane. Each spin column was then placed in a 
fresh 1.5ml eppendorf and 30j.il of RNase free water (Qiagen) was applied to each 
membrane to elute the RNA. Each column was centrifuged at 10,000rpm for 1 
minute after which the eluate from the eppendorf was re-applied to each membrane 
and centrifuged again to increase the RNA yield. RNA was quantified using the 
Nanodrop spectrophotometer (Thermo Scientific) and stored at -80°C until further
2.4.2 Reverse transcription
Reverse transcription is the process in which a single strand of RNA is transcribed in 
to complementary DNA (cDNA) using a reverse transcriptase enzyme. The reverse 
transcriptase enzyme used is the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) enzyme (Invitrogen). To a 0.2ml domed nuclease-free 
microcentrifuge tube (Starlab, Ahrensburg, Germany) 1 |j,g of sample RNA was 
added, 0.5p.1 of 500pg/ml oligo dT (Invitrogen), 0.5|il of lOmM deoxyribonucleotide
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triphosphates (dNTP) mix (lOmM each of dATP, dTTP, cCTP and dGTP) 
(Invitrogen) and RNase-free water (Qiagen) to a total volume of \2\A. This is heated 
to 65 °C for 5 minutes using a thermal cycler (DNA Engine Tetrad 2, Peltier Thermal 
Cycler, BioRad, Hercules, CA) and then placed on ice. To each sample 2pl of 5x 
first strand (FS) Buffer, 1 (xl of 0.1M dithiothreitol (DTT) and 0.5|il ofRNasin 
inhibitor (Promega) was added. After gentle mixing, each sample was incubated at 
37°C for 2 minutes after which 0.5|o,l (100 units) of M-MLV RT was added to each 
sample, apart from the negative control sample, followed by a further incubation for 
50 minutes at 37°C in the thermal cycler. The samples were then heated to 70°C for 
15 minutes to inactivate the reaction after which they were stored at -20°C until 
further use.
2.4.3 Polymerase chain reaction (PCR)
Polymerase chain reaction (PCR) is a technique used to amplify segments of DNA 
using the DNA obtained in the reverse transcription step as templates from which a 
new DNA strand is produced. Specific DNA primers are used to initiate DNA 
synthesis and to ensure amplification of the region of interest within the DNA 
template. The primers are non-complementary and are present in excess in the 
reaction. Primers were designed using Oligoperfect software (Invitrogen) and were 
purchased from Invitrogen. Details of primers used are listed in table 2.5. As well as 
the DNA template and primers, Thermus aquaticus (Taq) DNA polymerase enzyme 
and the dNTPs are included to achieve amplification of the DNA fragment of 
interest. The concentration of the PCR reaction reagents is detailed in table 2.6 to a 
total volume of 50|xl.
Table 2.4 Primers used to amplify DNA
PCR Sequence (5’ - 3’)
ß-Actin Forward 
ß-Actin Reverse 
pS2 Forward 
pS2 Reverse
T CACCCACACTGTGCCCATCT A 
CAGCGGAACCGCTCATTGCCA 
GTCCCCTGGTGCTTCTATCC 
GAGTAGT C AAAGT C AG AGCAGTC AAT CT
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Table 2.5 PCR reaction reagents
Component Volume (|il)
cDNA 3(0.1
lOx PCR Buffer 5jj.1
50mM MgCl 1.5hI
0.1 (iM pS2 primers 1 jj.1
lOmM dNTP mix 1 fxl
Taq DNA polymerase 0.25|il
RNase free water 38.25(xl
PCR reactions were performed using a thermal cycler. Following incubation at 94°C 
for 3 minutes to achieve DNA denaturation, each reaction comprised a number of 
different stages (table 2.7) as described below:
• DNA denaturation - sample is heated to 94°C for 45 seconds to ensure DNA 
denaturation.
• Primer annealing - temperature is reduced to allow the primers to anneal to 
the target DNA.
• Extension - DNA polymerase adds dNTPs in the 5’ to 3’ direction to 
synthesise a new cDNA strand.
• The denaturation-annealing-extension cycle is repeated with the sequence of 
interest between the primers exponentially increased with each cycle.
• Final elongation - following the last cycle, a final ten minute incubation at 
72°C is performed to ensure that any remaining single-stranded cDNA is 
fully extended.
Table 2.6 Cycling conditions for PCR reactions
PCR Product Denature Anneal Extend No. of
Temp Time
(°C) (s)
Temp Time
(°C) (s)
Temp Time
(°C) (s)
Cycles
B-Actin mRNA 94 45 60.0 30 72 60 35
pS2 mRNA 95 60 60.0 1 2 0 72 120 25
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2.4.4 PCR analysis using D N A  agarose gels
PCR products were analysed using agarose gel electrophoresis to separate products 
according to size. Agarose powder (Promega) was heated in lx  Tris acetate EDTA 
(TAE) Buffer (Appendix I) at a concentration of 1.5% (0.75mg agarose in 50mls 
TAE). After cooling, 7(xl of Sybersafe (Invitrogen), (used as an intercalating agent) 
was added to the gel which was then poured into a casting rig containing a well- 
comb and allowed to solidify at room temperature. Once set, the gel was covered 
with lx  TAE Buffer and the samples and loading dye were added to each well. An 
electric current of 1 0 0 V was then applied to the gel for 30 minutes allowing for 
adequate migration of the samples. Gels were visualised using ultraviolet light with 
the images recorded using the LAS3000 Image software (Fujifilm, Japan).
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2.5 Epigenetic studies
As described in 1.3.2, epigenetic modifications are a mechanism by which loss of 
gene transcription can occur in the absence of gross mutations. Méthylation of 
specific CpG regions within the promoter region of genes can result in the loss of 
gene expression.
2.5.1 DNA extraction
Cells were cultured in T25 flasks until they reached 90% confluency. They were then 
treated as described in section 2.1.7 for 24 hours. DNA extraction was performed 
using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) following the 
manufacturer’s instructions. Cells were harvested as described in 2.1.5 after which 
they were resuspended in 200pl of PBS. 20|il of proteinase K was added to each 
solution followed by the addition of 200pl of Buffer AL and the solution was 
vortexed to ensure a homogenous mixture. They were incubated at 56°C for 10 
minutes, 2 0 0 (il of 1 0 0 % ethanol was added to each sample which was then 
transferred to a DNeasy spin column and centrifuged for 1 minute at 8,000rpm. The 
flow through was discarded and the membrane washed with 500(j.l of Buffer AW1 
after which it was again centrifuged for 1 minute at 8,000rpm. 500ill of Buffer AW2 
was added to the membrane and the sample centrifuged for 3 minutes at 14,000rpm. 
The column was then placed in a 1.5ml eppendorf, 200|il of Buffer AE was added to 
the membrane and the sample was left to stand at room temperature for 1 minute. It 
was the centrifuged for 1 minute at 8 ,0 0 0 rpm with the sample from the eppendorf re­
applied to the membrane and centrifuged again to increase the DNA yield. DNA was 
quantified using the Nanodrop spectrophotometer (Thermo Scientific) and stored at - 
20°C until further use.
2.5.2 Bisulfite conversion and sequencing
The aim of bisulfite conversion is to identify the methylated and unmethylated CpG 
islands within the promoter region of interest. When unmethylated DNA is treated 
with bisulfite, the cytosine residues are converted to uracil residues. However, when
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there is a methyl group attached to the cytosine residue, this prevents the conversion 
occurring and it remains a cytosine residue. Therefore, bisulfite conversion results in 
specific changes occurring to DNA sequences that are dependent on the methylation 
status of the cytosine residues. During PCR amplification, the uracil is converted to 
thymidine which can be identified using specific primers. This can therefore 
determine the methylation status of a segment of DNA, in the case of this research, 
the promoter region of ER.
Bisulfite conversion was performed using the EZ DNA-methylation Gold Kit 
(Zymo, CA, USA) following the manufacturer’s instructions. 130p.l of CT 
Conversion Reagent was added to 500ng of DNA with the total volume increased to 
20(j.l using RNase free water (Qiagen). The sample was pipette mixed and then 
heated in a thermal cycler at 98°C for 10 minutes followed by 64°C for two and a 
half hours. The sample was then loaded in to a Zymo-Spin IC Column (Zymo) along 
with 600|il of M-Binding Buffer and was centrifuged at 13,000rpm for 30 seconds 
with the flow-through then discarded. 1 OOfxl of M-was Buffer was added with the 
sample centrifuged at 13,000rpm for 30 seconds. 200|il of M-Desulphonation Buffer 
was added and the column left to stand at room temperature for 15 minutes and then 
centrifuged at 13,000rpm for 30 seconds. It was washed with 200(j,l of M-Wash 
Buffer and centrifuged at 13,000rpm for 30 seconds which was repeated a second 
time. The column was transferred to a 1.5ml microcentrifuge tube, lOpl of M- 
Elution Buffer was added to the membrane and it was centrifuged at 13,000rpm for 
30 seconds to elute the DNA which was stored at -20°C until further use.
Samples were then sent for sequencing to MWG Biotech (Ebersberg, Germany) 
using primers as detailed in table 2 .8 , which had been used previously in the 
identification of methylated and unmethylated ER (Lapidus, Nass et al. 1998; 
Pirouzpanah, Taleban et al. 2010).
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Table 2.7 Prim ers used to am plify  methylated and unmethylated ER
PCR Sequence (S’ - 3’)
Methylated ER Forward 
Methylated ER Reverse 
Unmethylated ER Forward 
Unmethylated ER Reverse
GAT ACGGTTT GT ATTTT GTTCGC 
CG AACGATT C A AAAACT CCA ACT 
GGATATGGTTTGTATTTTGTTTGT 
ACAAACAATTCAAAAACTCCAACT
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2.6 Translational Research
Ethical approval for all studies using patient tissue samples was obtained from the 
Medical Ethics Committee, Beaumont Hospital, Dublin 9 and Waterford Regional 
Hospital, Co. Waterford. Samples were only used from patients who provided 
informed consent for the use of their tissue in any subsequent translational research. 
All patients who presented with breast cancer between 1996 and 2008 were included. 
The only exclusion criterion was patients who were diagnosed with metastatic 
disease at presentation.
Table 2.8 Demographics of the patient cohort used to construct the tissue 
microarray
Patient Demographics Number of Patients
Total number of patients 488
Median age 56.6 years (range 28.5 -  92.6)
Median follow-up 4.29 years (range 0.4 -  13.9)
Receptor status
ER positive 342 (70.0%)
PR positive 262 (53.7%)
HER2 positive 147 (30.1%)
Tumour grade
Grade I 67 (13.7%)
Grade II 220 (45.1%)
Grade III 201 (41.2%)
Tumour stage
1 157 (32.2%)
2 263 (53.9%)
3 62 (12.7%)
4 7(1.4%)
Positive lymph nodes 236 (48.4%)
Tumour recurrence 147 (30.1%)
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2.6.1 Im m unohistochem istry
Immunohistochemistry is a staining technique that is used to identify the presence 
and location of specific proteins within tissue specimens, in this case pS2. 
Immunohistochemistry was performed on previously constructed tissue micro-arrays 
that were constructed using formalin fixed paraffin embedded tissue. The tissue 
micro-arrays consisted of 0.8mm diameter cores of tumour specimens. Sections were 
taken at a thickness of 5pm using a microtome and mounted on Superfrost Plus 
slides (VWR International, Leuven, Germany).
All slides were baked for 4 hours at 65°C after which they were deparaffinised by 
soaking in xylene for a total of 6  minutes. Subsequent rehydration was performed by 
passage through industrial methylated spirits (100% for 6  minutes and 70% for 3 
minutes). The slides were then washed twice in PBS for 5 minutes. The activity of 
endogenous peroxidase was depleted by incubating the slides twice in 3% hydrogen 
peroxide (H2 O2 , Sigma Aldrich) in the dark for 10 minutes. They were then washed 
in double-distilled H2O for 5 minutes followed by a wash in PBS with 0.1% Tween 
(Sigma Aldrich) (PBST) for 5 minutes. Antigen retrieval was performed by heating 
the slides in lOmM sodium citrate buffer (pH 6.0) for 7 minutes in an enclosed 
plastic container using a domestic microwave. The slides were then cooled on the 
bench in the sodium citrate buffer for another 2 0  minutes followed by a further two 
washes in PBST for 5 minutes each.
Pre-incubating the slides at room temperature for 90 minutes in a 3% solution of 
goat serum (same species from which the secondary antibody was raised) reduces the 
binding of secondary antibody to non-specific endogenous immunoglobulins. 
Primary pS2 antibody (Novocastra, Leica Microsystems, Germany) concentration 
was determined according to the manufacturer’s instructions and subsequent 
optimisation with a concentration of 1:300 found to result in optimal staining of 
slides. Slides were incubated in primary antibody at 4°C overnight. Following 3 
washes in PBST for 5 minutes each, the slides were then incubated for 30 minutes at 
room temperature in the Vectastain Elite PK-1600 series biotinylated goat secondary 
antibody (Burlingame, CA) which was diluted by a factor of 1:200 in PBS 
containing 15jal of the goat blocking serum. Amplification of the signal was
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achieved by incubating the slides for a further 30 minutes at room temperature in the 
Avidin-biotin complex from the Vectastain Elite kit. Diaminobenzidine 
tetrahydrochloride (DAB) (Sigma Aldrich) was applied to the slides for 5 minutes to 
develop the product. The DAB reaction was stopped by washing the slides in 
double-distilled H20  for 5 minutes. Counter-staining was achieved by incubating the 
slides in haematoxylin (Sigma Aldrich) for 3 minutes at room temperature after 
which the slides were washed in flowing water for 5 minutes. Dehydration of the 
slides was performed by passing them through 70% IMS for 3 minutes followed by 
two 3 minute passages through 100% IMS with two subsequent 3 minute passages in 
xylene. Coverslips were applied by mounting the slides with DPX mounting solution 
(Sigma Aldrich).
Stained slides were reviewed by two observers using light microscopy and scored 
according to the Allred scoring system (Allred, Clark et al. 1993). This system 
scores slides according to two variables: the area of tissue stained (none =0 , < 1 %=1 , 
>1% but <10%=2, >10% but <33%=3, >33% but <66%=4 and >66%=5) and the 
average intensity of staining of tumour cells (none=0 , weak=T, intermediate=2 , 
strong=3). This results in a combined score ranging between 0 and 8 . A total score of 
three or greater was deemed positive.
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2.7 Statistical Analysis
Anonymous databases were maintained on Microsoft Excel (Microsoft, WA, USA). 
Statistical analyses were carried out using StatsDirect software (Chesire, UK). P 
values <0.05 were considered significant. Each experiment was carried out three 
times (i.e. n=3) with the mean result and standard error presented. Densitometry was 
performed using ImageJ software, version 1.45 (National Institute of Mental Health, 
USA). For molecular studies the probability of difference between two paired 
samples was analysed using a two tailed paired Student’s t-Test. Multivariate 
analysis was performed using STATA 10 data analysis software (Stata Corp. Texas, 
USA) and was carried out using Cox’s proportional hazard model, using the Breslow 
method for ties. Survival times between groups were compared using the Wilcoxon 
Breslow test adjusted for censored values.
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C h a p t e r  3
Identifying the effects of trastuzumab treatment on the 
steroid hormone pathway in vitro
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3.1 In troduction
Resistance to adjuvant therapies, whether de novo or acquired, adversely effects the 
overall prognosis of a person with breast cancer. While the benefits of tamoxifen 
therapy are well established (Group 1992; Osborne 1998), the phenomenon of 
acquired resistance is also widely documented (Group 1992; Kurebayashi 2005). As 
previously discussed in chapter 1.5, one proposed mechanism of tamoxifen 
resistance is through crosstalk between the steroid hormone and growth factor 
receptor pathways (Schiff, Reddy et al. 2000; Razandi, Pedram et al. 2003; Shou, 
Massarweh et al. 2004; Osborne, Shou et al. 2005). This has been demonstrated in a 
number of phase II clinical trials which have shown that the use of gefitinib, a 
tyrosine kinase inhibitor that targets HER1, in combination with anti-oestrogen 
therapy, can improve the progression free survival in ER positive, HER2 negative 
breast cancers (Cristofanilli, Valero et al. 2010; Osborne, Neven et al. 2011)
Similarly, crosstalk between the two signalling pathways has been implicated in the 
development of acquired resistance to lapatinib, a small-molecule tyrosine kinase 
inhibitor that inhibits signalling through the growth factor receptor pathway by 
reversibly binding to HER1 and HER2 (Xia, Bacus et al. 2006). Xia et al suggest 
that, as a result of this crosstalk, the efficacy of lapatinib might be enhanced if used 
in combination with anti-oestrogen therapies such as a selective oestrogen receptor 
downregulator e.g. fulvestrant, or an aromatase inhibitor. This combination therapy 
might even be relevant in breast cancers that are technically deemed to be ER 
negative based on diagnostic criteria but still express detectable ER.
In humans, chromosome 6  encodes for the ER protein gene which comprises eight 
exons separated by seven intronic regions, spanning more than 140 kilobases (Green, 
Walter et al. 1986; Greene, Gilna et al. 1986). It contains eight coding regions which 
are transcribed from at least seven promoters (Kos, Reid et al. 2001; Herynk and 
Fuqua 2004). Transcription of this gene results in the formation of a number of 
forms of ER including truncated versions whose sizes can vary and splice variants 
(Fuqua, Fitzgerald et al. 1992; Kos, Denger et al. 2002; Al-Bader, Al-Saji et al. 
2010). Most commonly, ER is observed at 6 6 kDa (Walter, Green et al. 1985).
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A n a ly s is  o f  the fu n ctio n a l a c tiv ity  o f  E R  w ith in  our breast can cer c e lls  required  the 
use o f  a target gene w hose e xp re ssio n  is  kn o w n  to be dependent on  the a ctiv ity  o f  
E R . p S 2 , a lso  kn o w n  as tre fo il fa cto r 1, is  a sm all cy ste in e -rich  p rotein  w hose 
e xp ressio n  has been revealed  to be dependent on an a ctive  E R . Th erefo re , in  th is 
study th is c la ss ic a l E R  target gene w as used to dem onstrate a c tiv ity  o f  E R  w ith in  the 
c e ll lin e s.
T h e  in teractio ns betw een the stero id  horm one and grow th  fa cto r receptor pathw ays 
are undo ubted ly e xtre m e ly  in tricate  and co m p lex. C ro ssta lk  in v a ria b ly  p la y s an 
in te g ra l ro le  in  the develo pm ent o f  acq u ired  resistan ce  to tam o xife n  and p o ss ib ly  
other anti-o estro gen  therap ies. In  v itro  m odels su ggest that it  m igh t a lso  be a facto r 
in  the developm ent o f  resistan ce  to sm a ll-m o le cu le  tyro sin e  k in a se  in h ib ito rs such  as 
lap atin ib . O n  th is  b ackgro u n d , the e ffect o f  trastuzum ab on the stero id  horm one 
pathw ay w as in ve stigate d  in  breast can cer c e ll lin e s to determ ine w hether or not it 
had an  e ffe ct on  the stero id  horm one pathw ay thereby in d ica tin g  the presence o f 
c ro ssta lk  betw een the tw o p athw ays.
3 .2  A im s :
T h e  a im s o f  th is  chapter re late  to the firs t  o b je ctive  o f  the study: to in ve stigate  the 
e ffect o f  trastuzum ab treatm ent on the stero id  horm one pathw ay in  the breast cancer 
c e ll lin e s. T h e  fo llo w in g  sp e c ific  o b je ctive s w ere d efin ed :
a. ch aracterise  the effect o f  trastuzum ab treatm ent on  the exp ressio n  o f 
E R  in  the breast can cer c e ll lin e s.
b. determ ine the e ffect o f  trastuzum ab treatm ent on the tran scrip tio n al 
a c tiv ity  o f  the stero id  horm one pathw ay in  the c e ll m odel.
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3.3 Results:
3 .3 .1  E ffe c t  o f  tra stu zu m a b  tre a tm e n t on  E R  p ro te in  e x p re ss io n  in  M C F -7 , 
L C C - 1  an d  S K B R - 3  b re a st c a n c e r c e ll lin e s
E R  protein  e xp ressio n  can  p la y  a ro le  in  the re sp o n siven e ss o f  c e lls  to endocrine 
therap ies. T o  exam in e  the effect o f  trastuzum ab on E R  p ro te in  exp ressio n  in  the 
breast can cer c e ll lin e s, c e lls  w ere treated w ith  lO O pM /m l trastuzum ab fo r 24 hours 
after w h ich  e xp re ssio n  o f  E R  p rotein  w as evaluated  u sin g  w estern b lo ttin g  
techn iq ues. A l l  exp erim en ts w ere perform ed in  trip lica te  (n = 3 ) w ith  the m ean 
e xp ressio n  and standard e rro r ca lcu late d . A s  show n in  fig u re  3 .1 , M C F -7  c e lls  had 
the h ig h est e xp re ssio n  o f  b a sa l le v e ls  o f  E R , w ith  L C C - 1  c e lls  o n ly  e xp re ssin g  a lo w  
b asa l le v e l and S K B R -3  c e lls  not e xp re ssin g  detectable le v e ls  o f  E R  at a ll. Treatm ent 
w ith  trastuzum ab w as fo u n d  to s ig n ific a n tly  increase  E R  p ro te in  e xp ressio n  in  the 
M C F -7  c e lls  (m ean in crease  =  2 .0 9  + /- 0 .2 4 7 ; p = 0 .0 4 8 ) w h ile  there w as no 
s ig n ific a n t change in  p ro te in  e xp re ssio n  in  the L C C - 1  c e lls  (m ean decrease =  0.77 
+ /- 0 .0 5 8 3 ; p = 0 .0 6 ). T rastu zu m ab  treatm ent w as noted to re su lt in  the exp ressio n  o f 
E R  in  the S K B R -3  c e lls  (m ean in crease  =  8.22 + /- 1.45; p = 0 .0 3 8 ).
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Figure 3.1: A  - Western b lo t analysis o f ER expression in protein lysates from  M CF- 
7, LCC-1 and SKBR-3 cells. Cells were treated w ith lOO/uMZml trastuzumab fo r  24 
hours p rio r to perform ing western b lot analysis. Treatment w ith trastuzumab 
resulted in a significant increase in ER protein expression in M CF-7 cells 
(p=0.048), no change in ER protein expression in LCC-1 cells and expression ofER  
in SKBR-3 cells (p=0.039).
B  —  densitometry graph illustra ting  the changes in ER expression fo llow in g  
treatment w ith trastuzumab. The asterisks indicate statistically significant changes.
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3 .3 .2  E ffe c t  o f tra stu zu m a b  tre a tm e n t on the  t ra n s c r ip t io n a l a c t iv ity  o f the  
ste ro id  h o rm o n e  p a th w a y  in  M C F -7  a n d  L C C - 1  b re a st c a n c e r c e ll lin e s
T h e  e ffe ct o f  trastuzum ab and E 2 treatm ent on the tra n scrip tio n a l a ctiv ity  o f  the 
stero id  horm one pathw ay in  the M C F -7  and L C C -1  c e ll lin e s w as assessed u sin g  a 
D u a l L u c ife ra se  R e p o rter A s s a y  System . C e lls  w ere treated w ith  1 OOjiM /m l 
trastuzum ab and 10 '8 E 2 fo r 6 ho u rs p rio r to p erfo rm in g the lu c ife ra se  assay. E a ch  
a ssa y  w as perform ed in  trip lica te  and repeated three tim es to determ ine the m ean 
e xp re ssio n  le v e ls  and standard e rro r rates. Treatm ent o f  M C F -7  c e lls  w ith  both E 2 
and trastuzum ab resu lted  in  u p reg u latio n  o f  the tra n scrip tio n a l a ctiv ity  o f  the steroid  
horm one pathw ay as dem onstrated b y  the increased a ctiv ity  o f  the P G L 3 -p S 2  
prom oter (m ean increase  =  3 .6 1 4  + /- 0 .6 9 1 ; p = 0 .0 6  fo r E 2; m ean increase  =  2 .5 46  +/- 
0 .1 5 9 ; p = 0 .0 0 9 7  fo r trastuzum ab) (fig u re  3 .2 ). In  the L C C - 1  c e lls  there w as no 
n o ticeab le  d iffe re n ce  in  prom oter a c tiv ity  after both treatm ents (m ean increase  =  
1.446 + /- 0 .0 84; p = 0 .0 9  fo r E 2; m ean in crease  =  0.801 + /- 0 .1 0 7 ; p =0 .43  fo r 
trastu zu m ab ).
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Figure 3.2: Luciferase assay demonstrating the effect o f E} and trastuzumab on the 
transcriptional activity o f the steroid hormone pathway. Cells M’ere treated w ith I f f  
8M  E2 and lOOfxM/ml trastuzumab fo r  6 hours p rio r to perform ing luciferase assay. 
E2 and trastuzumab increased transcriptional activity in M CF-7 cells (mean 
increase =  3.614 + /- 0.691; p = 0 .06fo r  E2; mean increase =  2.546 + /- 0.159; 
p= 0.0097 fo r trastuzumab) (A) while there was no significant change in activity in 
LCC-1 cells fo llow in g  treatment (mean increase =  1.446 + /- 0.084; p = 0 .09 fo r  E2 ; 
mean increase =  0.801 + /- 0.107; p = 0 .43 fo r  trastuzumab) (B). The asterisk 
indicates a statistically significant change.
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R e la tiv e  p S 2  m R N A  le v e ls  w ere a lso  in ve stigate d  u sin g  reverse tra n scrip tio n  P C R  
(R T - P C R )  in  the three breast cancer c e ll lin e s treated w ith lO O jiM /m l trastuzum ab, 
10'8 4 -O H T  and 1 O'8 E 2 fo r 6 hours both separately and in  co m b in atio n . A ll  
experim ents w ere perform ed three tim es to determ ine the m ean and standard error 
rates. In  the M C F -7  c e lls , treatm ent w ith  E 2 resu lted  in  s ig n ific a n tly  increased  le v e ls 
o f  p S 2  m R N A  e xp re ssio n  (m ean in crease  =  2.281 + /- 0 .1 3 1 ; p = 0 .0 1) w h ilst 4 -O H T  
s ig n ific a n tly  reduced e xp re ssio n  le v e ls  (m ean  decrease =  0.718 + /- 0 .0 2 7 ; p = 0 .0 0 9 ). 
Treatm ent w ith  trastuzum ab w as found  to increase  p S 2  m R N A  le v e ls  a lm o st to a 
s im ila r le v e l as seen fo llo w in g  treatm ent w ith  E 2 (m ean increase  =  1.741 + /- 0/157; 
p = 0 .0 4 2 ) T h e  ad d itio n  o f  4 -O H T  to both E 2 and w as found  to reduce p S 2  le v e ls to 
near b a se lin e  (m ean in cre ase  =  1.235 + /- 0 .08  fo r E 2 and 4 -O H T , m ean increase  =  
1.285 + /- 0.118 fo r trastuzum ab and 4 -O H T ) (fig u re  3 .3 ). T he re  w ere no s ig n ific a n t 
d iffe re n ces found  in  p S 2  m R N A  e xp re ssio n  le v e ls  in  L C C - 1  c e lls  fo llo w in g  the 
va rio u s treatm ents (m ean in crease  =  1.015 + /- 0 .0 44; p = 0 .7 6  fo r E 2, m ean increase =  
1.067 + /- 0 .0 1 4 ; p = 0 .3 5 9  fo r 4 -O H T , m ean decrease =  0 .945 +/- 0 .0 9 4 ; p =0 .731 fo r 
E 2 and 4 -O H T , m ean in cre ase  =  1.362 + /- 0 .0 5 ; p =0 .3 0 5  fo r trastuzum ab and m ean 
increase  =  1.063 + /- 0 .0 1 5 ; p = 0 .8 0 7  fo r trastuzum ab and 4 -O H T ) (fig u re  3 .4 ). 
Treatm ent o f  S K B R -3  c e lls  w ith  E 2 had m in im al e ffect on  p S 2  m R N A  e xp ressio n  
le v e ls  (m ean in crease  =  1.015 + /- 0 .0 4 4 ; p = 0 .2 4 6 ) as d id  4 -O H T  treatm ent (m ean 
in crease  =  1.067 + /- 0 .0 1 4 ; p = 0 .4 3 1 ). H o w e ve r, fo llo w in g  treatm ent w ith  
trastuzum ab, there w as a s ig n ific a n t increase  in  p S2  m R N A  le v e ls  noted (m ean 
in crease  =  1.362 + /- 0 .0 4 5 ; p = 0 .0 1 5 ) (fig u re  3 .5 ).
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F igure  3.3: A  - RT-PCR expression o f pS2 mRNA in M CF-7 cells under the 
influence o f 10'8ME2, 1 O'8M tam oxifen and l00piM /m l trastuzumab, individually and 
in  combination. mRNA levels were significantly increasedfollow ing Eo (mean 
increase = 2.281 + /- 0.131; p = 0 .01) and trastuzumab (mean increase = 1.741 + /- 
0/157; p=0.042) treatment and reducedfollow ing tamoxifen treatment (mean 
decrease =  0.718 + /- 0.027; p = 0 .009).
B  — densitometry graph illustra ting  the increase in pS2 mRNA expression fo llow ing  
treatment w ith E2 and trastuzumab and the decrease fo llow in g  4-OHT treatment.
The asterisks indicate statistically significant changes in expression levels.
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Figure  3.4: A  - RT-PCR expression o f pS2 mRNA in LCC-1 cells under the influence
8 8
o f 10' M E 2, 10' M  tamoxifen and lOOjuMZml trastuzumab, individually and in  
combination. mRNA levels were unchanged fo llow in g  a ll treatments (mean increase 
= 1.015 + /- 0.044;p = 0 .76fo r  Eo, mean increase =  1.067 + /- 0.014;p = 0 .359fo r  4- 
OHT, mean decrease = 0.945 + /- 0.094; p = 0 .731 fo r  E2 and 4-OHT, mean increase 
=  1.362 + /- 0.05; p = 0 .305fo r  trastuzumab and mean increase =  1.063 + /- 0.015; 
p= 0 .8 0 7 fo r trastuzumab and 4-OHT).
B  -  densitometry> graph illustra ting  the sim ila r expression o f pS2 mRNA levels in 
LCC-1 cells fo llo w in g  treatments.
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Figure  3.5: A  - RT-PCR expression o f pS2 tnRNA in SKBR-3 cells under the 
influence o f 1 O'8M  E i, 1 O'8M  tamoxifen and 100/uMZml trastuzumab, individually and 
in  combination. Treatment o f SKBR-3 cells w ith E2 had m inim al effect on pS2 mRNA 
expression levels (mean increase =  1.015 + /- 0.044;p=0.246) as d id 4-OHT  
treatment (mean increase = 1.067 + /- 0.014; p = 0 .431). However, fo llow in g  
treatment w ith trastuzumab, there was a significant increase in pS2 mRNA levels 
noted (mean increase = 1.362 + /- 0.045; p=0.015)
B  -  densitometry graph illustra ting  the increase in pS2 mRNA expression in SKBR-3 
cells fo llo w in g  treatment w ith trastuzumab but not w ith E2. The asterisk indicates a 
statistically significant change.
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3.3 .3  T ra s tu z u m a b  in d u c e d  e xp re ssio n  o f E R  in  S K B R - 3  b re a st c a n c e r ce lls  
th ro u g h  d é m é th y la tio n
A s  dem onstrated ab o ve, treatm ent o f  E R  n eg ative  S K B R -3  c e lls  w ith  trastuzum ab 
resu lts in  the e xp ressio n  o f the E R  p ro te in  (fig u re  3 .1 ). O ttavian o  et a l have 
p re v io u sly  dem onstrated that m éth ylatio n  o f  C p G  isla n d s w ith in  the prom oter re g io n  
o f  the E R  gene can  re su lt in  the lo ss o f  e xp re ssio n  o f  E R  (O tta v ia n o , Is sa  et a l.
1994). Treatm ent o f  E R  n egative  breast can cer c e lls  w ith  a D N A  m ethyltransferase  
in h ib ito r re su lts in  dém éth ylatio n  o f  the E R  C p G  isla n d s and subsequent exp ressio n  
o f E R  p ro te in  (Fe rg u so n , L a p id u s  et a l. 1995). T o  determ ine w hether trastuzum ab 
treatm ent o f  S K B R -3  c e lls  resu lted  in  d ém éth ylatio n  o f  C p G  isla n d s w ith in  the 
prom oter re g io n  o f  the E R  gene w ith  subsequent e xp re ssio n  o f  a  fu n ctio n a l E R , 
m éth ylatio n  stu d ies w ere perform ed fo llo w in g  treatm ent o f  c e lls  w ith  1 OOuM/m.1 
trastuzum ab fo r 24  h ours. T h e  re su lts show  that out o f  fiv e  detectable C p G  isla n d s 
w ith in  the E R  prom oter re g io n  (fig u re  3 .6 ), a ll fiv e  w ere unm ethylated in  M C F -7  
c e lls  in  both v e h ic le  and trastuzum ab treated sam ples (fig u re  3 .7 , tab le  3 .1 ). In  the 
S K B R -3  c e lls , a ll f iv e  is la n d s w ere m ethylated  p rio r to trastuzum ab treatm ent, w ith  
a ll b eco m in g unm ethylated  fo llo w in g  treatm ent (fig u re  3 .7 , fig u re  3 .8 , tab le  3 .2 ).
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Figure 3.6: Demonstrates the clone sequence chromatogram o f the DNA region fo r  
the ER gene. The CpG islands are highlighted by the stars. In  the M CF-7 cells these 
were unmethylated both before and after treatment w ith 100 fxM/ml trastuzumab. In  
the SKBR-3 cells these were methylated p rio r to treatment and unmethylated after 
treatment w ith 100 /iM /m l trastuzumab.
ACCCGTCAGATGCGATG w G e n e
i i i i i t i i i i i i i i i i i V  —  .
TGGGCAGTCTACGCTAC E x p r e s s i o n
Figure 3.7: Schematic representation o f unmethylated DNA sequence in M CF-7 
cells and in SKBR-3 cells fo llow in g  trastuzumab treatment resulting in ER gene 
expression.
*  $
ACCCGTCAGATGCGATG
I I I t 1 I I I I i I I r i  I I I
T G G ^ ^ G T C T A C ^ ^ A C
Figure 3.8: Schematic representation o f méthylation o f the DNA sequence in SKBR- 
3 cells inh ib iting ER gene expression
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T a b le  3 .1 : M é th y la tio n  stu d ie s a sse ss in g  C p G  is la n d s  w ith in  th e  p ro m o te r 
re g io n  o f th e  E R  gen e  in  M C F -7  c e lls
A l l  CpG islands were unmethylated both p rio r and subsequent to treatment w ith  
1 OOfiM/ml trastuzumab.
C p G  S ite 1 2 3 4 5
V e h ic le Unmeth Unmeth Unmeth Unmeth Unmeth
T ra s tu z u m a b Unmeth Unmeth Unmeth Unmeth Unmeth
T a b le  3 .2 : M é th y la tio n  stu d ie s a sse ss in g  C p G  is la n d s  w ith in  th e  p ro m o te r 
re g io n  o f th e  E R  gen e  in  S K B R - 3  c e lls
A ll CpG islands were methylated p rio r to treatment w ith 100/iMZml trastuzumab, 
w ith a ll unmethylated subsequent to trastuzumab treatment.
C p G  S ite 1 2 3 4 5
V e h ic le Methylated Methylated Methylated Methylated Methylated
T ra s tu z u m a b Unmeth Unmeth Unmeth Unmeth Unmeth
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3.4 Discussion
C ro ssta lk  betw een the stero id  endocrine pathw ay and the gro w th  facto r receptor 
pathw ay has been p re v io u sly  im p licate d  in  the developm ent o f  resistance  to an ti­
oestrogen therapies (S c h iff , R e d d y  et a l. 20 0 0 ; R a za n d i, Pedram  et a l. 2003; Sh o u , 
M assarw eh  et a l. 2004; O sb o rn e, Sh o u  et a l. 2 0 0 5 ). D e sp ite  a la rge  proportion  o f 
patients w ith  a m p lifica tio n  o f  the H E R 2  gene, in  p a rticu la r those w ith  m etastatic 
d isease, d eve lo p in g  re sistan ce  to a n ti-H E R 2  m onotherapies su ch  as trastuzum ab, the 
e xact m echan ism  b y w h ich  th is  resistance  d eve lo p s is  as yet unknow n. In  th is study 
it w as postulated that treatm ent o f  breast can cer c e lls  w ith  trastuzum ab co u ld  resu lt 
in  u p regu latio n  o f  the stero id  horm one pathw ay through  cro ssta lk  betw een the two 
pathw ays and therefore co u ld  re su lt in  the developm ent o f  resistance  to trastuzum ab.
T o  in ve stig ate  th is  h yp o th e sis three separate breast can cer ce ll lin e s w ere chosen to 
study the effects o f  trastuzum ab in vitro. D iffe re n tia l e xp re ssio n  le v e ls o f  E R  w as 
estab lish ed  in  the three c e ll lin e s. T h e  e ffect o f  trastuzum ab on the steroid  horm one 
pathw ay w as then determ ined through a num ber o f  techn iq ues e xa m in in g  the 
e xp re ssio n  and fu n ctio n a l a c tiv ity  o f  E R  fo llo w in g  treatm ent.
3 .4 .1  E R  p o sitiv e  e n d o c rin e  se n sitiv e  b re a st c a n c e r c e ll m o d e l
M C F -7  breast can cer c e lls , a w e ll estab lish ed  E R -e x p re ss in g  c e ll lin e  se n sitive  to 
endocrine therap ies, w ere used to study the e ffect o f  trastuzum ab in  E R  p o sitive  
c e lls . F o llo w in g  treatm ent w ith  trastuzum ab, these c e lls  w ere noted to have increased  
le v e ls  o f  E R  w hen com pared to b ase lin e  le v e ls . Fu rth er m o le cu la r studies co nfirm ed  
that th is incre ased  e xp re ssio n  enhances the tra n scrip tio n a l and fu n ctio n a l a ctiv ity  o f  
the stero id  horm one p ath w ay as dem onstrated b y  the increased  a ctiv ity  o f  the p S2  
prom oter as w e ll as e levated  le v e ls  o f  p S 2  m R N A .
T h e se  fin d in g s  corroborate the h yp o th esis o f  th is  study that c ro ssta lk  can o ccu r 
betw een the steroid  horm one pathw ay and the grow th  facto r receptor pathw ay 
w hereby treatm ent w ith  trastuzum ab can  re su lt in  u p regu latio n  o f the steroid  
horm one pathw ay.
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C ro ssta lk  betw een the tw o p ath w ays has a lread y been show n to re su lt in  resistance  to 
endocrine therapies (S c h iff , R e d d y  et a l. 20 0 0 ; R a za n d i, Pedram  et a l. 2003; Shou, 
M assarw eh  et a l. 20 0 4 ; O sb o rn e , Sh o u  et a l. 2 0 0 5 ) w h ich  has detrim ental 
consequences in  the fo rm  o f  tum our recurrence and p ro life ra tio n  that is  non- 
resp o n sive  to cu rren tly  a v a ila b le  therap ies. T h e  m o le cu la r p ath w ays behind the 
developm ent o f  resistance  to trastuzum ab are not yet as w e ll in ve stigate d  as those in  
endocrine resistan ce, but th e ir e ffect is  e q u a lly  d evastatin g. A s  d iscu ssed  in  sectio n  
1 .5 .2, a num ber o f  m echan ism s b y  w h ich  tum our c e lls  d eve lo p  resistance  to 
trastuzum ab have been in ve stig ate d  (M o lin a , S a e z et a l. 2 0 0 2 ; P ric e -S c h ia v i, Jepson  
et a l. 20 0 2 ; L u , Z i  et a l. 2 0 0 4 ; S c a ltr iti, R o jo  et a l. 20 0 7 ; W an g, X ia n g  et a l. 2 0 0 8 ), 
h ow ever our research  h ig h lig h ts  another p o ssib le  m echan ism  -  receptor cro ssta lk . 
T h is  fin d in g  has p o ten tia l co nsequences fo r the future c lin ic a l treatm ent o f  patients 
w ith  breast cancer. It  h ig h lig h ts  the n ecessity  to co n cu rre n tly  rather than se q u e n tia lly  
target the stero id  horm one pathw ay and the grow th  facto r receptor pathw ay to 
m in im ise  the u n co n tro lle d  stim u la tio n  o f  the stero id  horm one pathw ay w h ich  co u ld  
then lead  to c e ll p ro life ra tio n  and tum our recurrence. Fu rth er m o le cu la r stud ies are 
required  to id e n tify  the tra n scrip tio n  facto rs in v o lv e d  in  th is  cro ssta lk  to a llo w  fo r 
in d iv id u a lise d  patient therapy.
3 .4 .2  E R  p o sitiv e  e n d o c rin e  in s e n s itiv e  b re a st c a n c e r c e ll m o d e l
L C C - 1  c e lls , an iso g e n ic  d e riva tive  o f  M C F -7  c e lls , o ve rexp ress both E R  and H E R 2 . 
T h e y  are how ever in se n sitiv e  to oestrogen therapy and so w ere used to dem onstrate 
an endocrine in se n sitive  breast can cer c e ll m odel. A s  expected, there w as no 
response o b served  in  c e llu la r  a c tiv ity  w hen treated w ith  E 2. In te re stin g ly , there w as 
a lso  no s ig n ific a n t change in  e ither the e xp ressio n  o f  E R  or in  the tran scrip tio n a l or 
fu n ctio n a l a c tiv ity  o f  these c e lls  w hen treated w ith  trastuzum ab, u n lik e  the endocrine 
se n sitive  M C F -7  c e lls .
T h is  h ig h lig h ts  the p la s tic ity  o f  tum our c e lls , dem onstrating the v a ry in g  e ffect that 
id e n tica l treatm ents can  h ave  on the m o le cu lar p ath w ays in v o lv e d  in  c e llu la r grow th 
and p ro life ra tio n . Th e se  fin d in g s  show  that in  endocrine in se n sitiv e  breast cancer 
c e lls , the phenom enon o f  c ro ssta lk  betw een the tw o p ath w ays does not appear to 
o ccu r fo llo w in g  trastu zu m ab  treatm ent, u n lik e  that o bserved  in  endocrine sen sitive
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c e lls . T h is  su ggests a p o ssib le  lin k  betw een the se n sitiv ity  o f  c e lls  to oestrogen and 
the a b ility  o f  c e lls  to overcom e the a n ti-p ro life ra tiv e  e ffect o f  trastuzum ab through 
in te ractio n  w ith  the stero id  horm one p athw ay. Fu rth e r m o le cu la r stud ies are required 
to e lu cid ate  th is h yp o th e sis and determ ine w h y ce rta in  E R -e x p re ss in g  c e lls  show  
u p re gu latio n  o f  the stero id  horm one p ath w ay w h ile  others do not.
3 .4 .3  E R  n e g a tiv e  b re a st c a n c e r c e ll m o d e l
S K B R -3  c e lls  o verexp ress H E R 2  due to the a m p lifica tio n  o f  the c-e rb B 2  gene 
ho w ever they do not express E R  and so w ere used to dem onstrate a H E R 2  p o sitive , 
E R  n egative  c e ll m odel. B a se lin e  W estern  b lo ts fo r E R  e xp re ssio n  le v e ls  
dem onstrated that, as expected, E R  w as not expressed. H o w e ve r, subsequent 
treatm ent w ith  trastuzum ab not o n ly  resu lted  in  the e xp re ssio n  o f  E R , it  m ade it  
fu n ctio n a lly  active . Th e re fo re , not o n ly  can  trastuzum ab enhance the fu n ctio n  o f E R , 
it  can  cause a com plete sw itch  in  its  e xp re ssio n  in  ce rta in  c e lls , w h ich , as 
dem onstrated is  as a  re su lt o f  d em eth ylatio n  o f  the re le van t C p G  is la n d s w ith in  the 
prom oter re g io n  o f  E R .
D u a l treatm ent w ith  trastuzum ab and an anti-o estro gen  agent su ch  as tam o xifen  or an 
arom atase in h ib ito r h as been sh o w n  to restore the se n sitiv ity  o f  resistant c e lls  to an ti­
oestrogen therapies (B e n z , Sco tt et a l. 1992; K u n isu e , K u re b a y a sh i et a l. 2000; 
S a b n is, S c h a y o w itz  et a l. 2 0 0 9 ). R e ce n t data has a lso  show n that treatm ent o f  
le tro zo le -re sistan t c e lls  w ith  trastuzum ab can  restore c e llu la r E R  le v e ls  and thereby 
reverse  the developed resistance  to the arom atase in h ib ito r (S a b n is , S ch a y o w itz  et a l. 
2 0 0 9 ). H o w e ver, to date, there is  no data p u b lish ed  su g g e stin g  that trastuzum ab has 
the a b ility  to express a  fu n c tio n a lly  a ctive  E R  in  ce rta in  E R  n egative  breast cancer 
c e lls  or indeed tum ours. T h is  h as p o te n tia lly  s ig n ific a n t c lin ic a l im p lica tio n s.
C u rren t therapeutic re g im es do not in c lu d e  an ti-o estro gen  therapies i f  the breast 
can cer is  deem ed to be E R  n egative . H o w e ve r, i f  these sam e cancers are H E R 2  
p o sitiv e  they w o u ld  be co n sid ered  fo r therapeutic in terven tio n s su ch  as trastuzum ab 
i f  c lin ic a lly  in d icated . T h e  in v itro  fin d in g s  in  th is study w o u ld  su ggest that a 
p ro p o rtio n  o f these tum ours w o u ld  sw itch  from  b e in g  E R  n egative  to E R  p o sitive  
due to the dem eth ylatio n  e ffe ct o f  trastuzum ab re su ltin g  in  an untreated fu n ctio n in g  
stero id  horm one path w ay th ro u gh  w h ich  tum ours can  recu r and p ro life rate .
C h a p t e r  4
Translating the interaction between trastuzum ab and the 
steroid hormone pathw ay into the clinical setting
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4.1 Introduction
T ra n sla tio n a l stud ies enable research ers to recreate exp erim en tal hypotheses w ith in  
c lin ic a l sam ples to determ ine w hether in  vitro  fin d in g s co rrespond to s im ila r 
outcom es w ith in  the c lin ic a l arena. T h is  fundam ental research  to o l a llo w s fo r the 
q u ic k  and e ffic ie n t tran sfer o f  pertinent research  into m e d ica l therap ies, w ith  the 
p otentia l to s ig n ific a n tly  alter c lin ic a l p ractice  and patient outcom es.
In  order to assess w hether the in v itro  fin d in g s  correlated w ith  c lin ic a l outcom es, 
tran slatio n a l stu d ies w ere perform ed. T w o  hypotheses w ere in ve stigate d . F irs t ly , 
s im ila r to the exp erim en tal m odel, d id  treatm ent w ith  trastuzum ab resu lt in  
unregu lated  a ctiva tio n  o f  the stero id  horm one pathw ay? T o  dem onstrate th is 
h yp o th e sis, three patients w ere id e n tifie d  w ith  m etastatic d isease w ho rece ived  
trastuzum ab p rio r to rese ctio n  o f  th e ir breast cancer as w e ll as a m atched co ntro l 
patient w ho re ce ive d  n eo ad ju vant chem otherapy but d id  not re ce ive  trastuzum ab as 
she d id  not o ve r-exp ress H E R 2 . T issu e  from  the su rg ic a l resectio n  specim ens as w e ll 
as fro m  the pre-treatm ent core b io p sy  specim ens underw ent im m u n o h isto ch em ical 
a n a ly s is  (a s d escrib ed  in  2 .6 ) to determ ine e xp ressio n  o f  p S 2  and to assess fo r 
changes in  the tissu e  e xp re ssio n  le v e ls  o f  the E R  target gene to id e n tify  trastuzum ab- 
re lated  increased  a c tiv ity  o f  the stero id  horm one pathw ay.
Se co n d ly , it  w as endeavoured to e sta b lish  w hether the in v itro  re su lts had any 
s ig n ific a n t co rre latio n  w ith in  a  la rge  patient cohort. A fte r e sta b lish in g  the tissu e  
m icro a rra y  and gath erin g  the re le van t c lin ico p a th o lo g ic  d eta ils o f  a ll patients 
in c lu d in g  receptor status, tum our grade and stage, d isease recurrence as w e ll as 
va rio u s treatm ent re g im es su ch  as trastuzum ab therapy, im m u n o h isto ch em ica l 
a n a ly s is  w as perform ed o f  these specim ens to determ ine the tissu e  e xp ressio n  le v e ls 
o f  p S 2 . T h e  in  v itro  re su lts sh o w  that trastuzum ab in creases the a ctiv ity  o f  the stero id  
horm one p ath w ay thro u gh  receptor cro ssta lk . Therefo re  the c lin ic a l data w as 
an a lysed  to assess fo r a  co rre la tio n  betw een p S 2  e xp re ssio n  and the 
c lin ico p a th o lo g ic  param eters, in  p a rticu la r d isease recurrence and its re latio n sh ip  
w ith  the ad m in istratio n  o f  trastuzum ab w ith  a  v ie w  to e sta b lish in g  an activated
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steroid hormone pathway as the lin k  between trastuzumab treatment and disease 
recurrence.
4.2 Aims
The aim  o f  the w ork  presented in th is chapter was to investigate whether the in vitro 
find ings were translatable in to  the c lin ica l arena. The fo llo w in g  specific  objectives 
were defined:
a. Iden tifica tion  and im m unohistochem ical sta in ing o f  patients who 
received trastuzum ab p rio r to surgery w ith  a com parison o f  pS2 in tissue 
samples pre and post treatm ent
b. Im m unohistochem ica l s ta in ing  o f  a constructed tissue m icroarray to 
determ ine tissue expression levels o f  pS2
c. C orre la tion  o f  pS2 expression levels and disease recurrence w ith  various 
c lin icopa tho log ica l features o f  the relevant specimens
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4.3 Results
4.3 .1  Im m u n o h is to c h e m istry  fo r  p S 2  fo llo w in g  p re -o p e ra tiv e  tra stu zu m a b
T h e  use o f  trastuzum ab in  the neo ad ju vant settin g is  not cu rren tly  routine c lin ic a l 
p ractice  therefore the num ber o f  patients w ho h ave, to date, re ce ive d  trastuzum ab 
p rio r to su rg ic a l in te rven tio n  in  the tw o in stitu tio n s in v o lv e d  in  the study is  re la tiv e ly  
lo w . In  th is  stu d y, three patients w ith  H E R 2  p o sitive  breast can cer w ere id e n tified . 
T h e y  a ll presented w ith  m etastatic d isease  and so w ere in it ia lly  treated w ith  
trastuzum ab and chem otherapy, w ith  subsequent resectio n  o f  th e ir breast tum ours. 
T h e  m ean tim e to su rg e ry  w as 9 m onths (ran ge  2 - 1 5  m onths). A  case-m atched 
patient w ho re ce ive d  neo ad ju vant chem otherapy but not trastuzum ab as she d id  not 
o ve r-exp ress H E R 2  w as used as a co n tro l. Im m u n o h isto ch e m istry sta in in g  o f  both 
the pre-treatm ent core b io p sy  and the post-treatm ent su rg ic a l resectio n  specim en fo r 
p S 2  w as perform ed (fig u re  4 .1 ). U n fo rtu n a te ly , tissu e  fro m  the core b io p sy  o f  one o f 
the patients w ho re ce ive d  trastuzum ab p rio r to su rg ic a l re sectio n  w as not a va ila b le  
fo r in c lu s io n .
S ta in in g  o f  the pre-treatm ent core b io p sy  specim ens show ed lo w  e xp re ssio n  le v e ls  o f  
p S 2  w ith  b oth  o f  the post-treatm ent su rg ic a l re sectio n  specim ens show ed 
s ig n ific a n tly  stronger sta in in g  fo r p S 2 . B o th  the b io p sy  specim en and the su rg ic a l 
re se ctio n  sp ecim en  fro m  the co ntro l patient show ed s im ila r sta in in g  fo r p S 2  
in d ic a tin g  that the in creased  e xp re ssio n  observed in  the trastuzum ab treated patients 
w as not a re su lt o f  the chem otherapy. In stead  the increased  e xp ressio n  co u ld  be 
attributed to the a c tiv ity  o f  the stero id  horm one pathw ay b e in g  stim ulated  b y  
trastuzum ab as p re v io u sly  dem onstrated in vitro.
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F igure  4.1: Core biopsies (x200 m agnification) and surgical resection specimens 
(x600 m agnification) from  patients who received trastuzumab p rio r to surgery as 
w ell as a case-matched control patient were stained fo r  pS2 using 
immunohistochemistry. A &  B: patients who received trastuzumab p rio r to surgery 
had greater expression o f pS2 in the surgical resection specimens than core biopsy 
specimens. C: sim ilar expression o f pS2 was observed in a patient who received 
neoadjuvant chemotherapy but not trastuzumab as she did not over-express HER2.
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4.3.2 Immunohistochemistry of tissue microarray for pS2 expression
A s  d iscu ssed  in  2 .6 , fo llo w in g  e th ica l a p p ro va l, a tissu e  m icro a rra y  w as constructed 
fro m  p araffin -em b ed d ed  tissu e  sp ecim en s o f  breast can cers fro m  patients treated in  
both B eaum o nt H o sp ita l and W aterfo rd  R e g io n a l H o sp ita l. T issu e  sam ples fro m  a 
to ta l o f  488 patients w ith  breast can cer w ere stained and graded b y tw o in d iv id u a ls  
u sin g  the A llre d  sco rin g  system  (A llre d , C la rk  et a l. 1993) w ith  sam ples graded 
a cco rd in g  to the area o f  tissu e  stained and the average  in te n sity  o f  sta in in g  o f  tum our 
c e lls  (see se ctio n  2 .6 .1 ) . In  those tum our sam ples in  w h ich  p S 2  w as expressed, it  
w as dem onstrated w ith in  the cyto p la sm  o f  c e lls  (fig u re  4 .2 ). p S 2  w as fo u n d  to be 
expressed  in  ju s t  o ve r 7 0 %  o f  tissu e  sam p les, w h ich  is  in  ke ep in g  w ith  p re v io u sly  
docum ented e xp re ssio n  le v e ls  (So u b e yra n , W a ffla rt et a l. 1995). O n  u n ivariate  
a n a ly s is , the o n ly  c lin ic o p a th o lo g ic a l param eter that had a s ig n ific a n t d iffe re n ce  
betw een p S 2  p o sitiv e  and n egative  tum ours w as H E R 2  status, w ith  H E R 2  p o sitive  
tum ours le ss lik e ly  to exp ress p S 2  than  n eg ative  tum ours (p = 0 .0 4 8 ). O n  m u ltivaria te  
a n a ly s is , there w as no d iffe re n ce  noted in  tum ours that expressed  p S 2  to those that 
d id  not w ith  regard  to an y o f  the standard c lin ico p a th o lo g ica l param eters, in c lu d in g  
receptor status, lym p h  node m etastases, tum our stage or tum our grade.
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Figure  4.2: A tissue m icroarray containing 488 cores o f breast tumours was stained 
fo r  pS2 using immunohistochemistry. Images are representative fo r  a) tumour core 
negative fo r  pS2; b) tumour core positive fo r  pS2; c) tumour core stained w ith rabbit 
IgG  control. Images are xlOO m agnification (left) andx200 m agnification (right).
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4.4 Clinical ramifications of receptor crosstalk
T o  date, there is  no s ig n ific a n t data p u b lish ed  e xa m in in g  the e ffect o f  trastuzum ab on 
the steroid  horm one pathw ay and the c lin ic a l ra m ifica tio n s o f  th is cro ssta lk . S u rv iv a l 
a n a ly s is  o f  fo rty  H E R 2  p o sitive  patients w ho expressed p S2  on 
im m u n o h isto ch em istry (i.e . A llre d  score >  3 ) show ed that patients had a s ig n ific a n tly  
increased rate o f  recurrence i f  they re ce ive d  trastuzum ab com pared to those w ho did 
not (W ilc o x o n  B re slo w  test fo r e q u ality  o f  su rv iv o r functio n  p = 0 .0 3 1 5 ) (fig u re  4 .3 ).
Kaplan-Meier survival estimates - pS2 expressing patients
Ö
P=0.0315o
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Figure 4.3: Kaplan-M eier survival estimates were used to p lo t and compare disease 
recurrence in HER2 positive patients who expressedpS2 on immunohistochemistry. 
There were significantly more recurrence events noted during the fo llo w  up period  
in patients who received trastuzumab than patients who d id  not (Wilcoxon Breslow 
test fo r  equality o f survivor function p=0.0315).
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4.5 Discussion
In  th is  chapter im m u n o h isto ch em istry sta in in g  fo r p S 2  o f  a tissu e  m icro array 
co n ta in in g  sam ples from  alm o st fiv e  hundred breast can cer patients w as perform ed 
to co rre late  the in  v itro  fin d in g s  w ith  outcom es from  the c lin ic a l arena. T issu e  from  a 
second sm a lle r co ho rt o f  patients w ho re ce ive d  trastuzum ab p rio r to su rg ic a l 
in te rven tio n  w as a lso  stained. S ta tistica l a n a ly s is  w as perform ed to com pare sta in in g  
in te n sity  w ith  tum our c lin ico p a th o lo g ica l features and recurrence o f  d isease.
T h e  co rre la tio n  betw een p S 2  and standard c lin ic o p a th o lo g ic a l param eters su ch  as 
tum our grade and lym p h  node status has been w id e ly  debated w ith  som e studies 
fin d in g  an in ve rse  co rre latio n  betw een the tw o (Sto n e la ke , B a k e r et a l. 1994; R a c ca , 
C o n ti et a l. 1995; So u b eyran , W a ffla rt et a l. 1995; Io a ch im , T sa n o u  et a l. 2 0 0 3 ) and 
others fin d in g  no co rre la tio n  (Fo e ke n s, va n  Putten  et a l. 1993; G io n , M ione et a l. 
1995; N ic h o ls , Ib ra h im  et a l. 1995). W h ile  the percentage o f  p S 2 -e xp re ss in g  sam ples 
w as in  ke e p in g  w ith  p re v io u sly  p u b lish ed  stu d ies (So u b e yran , W a ffla rt et a l. 1995), 
s im ila r ly  there w as no s ig n ific a n t asso cia tio n  fo u n d  betw een p S 2  and standard 
c lin ico p a th o lo g ica l param eters. p S 2  has, how ever, been w e ll docum ented as an E R  
target gene (M a sia k o w sk i, B reath n ach  et a l. 1982; Prud'hom m e, F r id la n s k y  et a l. 
1985; M a y and W e stle y 1986; Fo e ke n s, van  Putten et a l. 1993). Th erefo re  p o sitive  
im m u n o h isto ch e m istiy  sta in in g  in  th is study h ig h lig h ts  as a ctive  stero id  horm one 
p athw ay. L o o k in g  s p e c ific a lly  at H E R 2  p o sitive  patients w ho a lso  had an active  
stero id  horm one path w ay in d icated  b y  th e ir e xp re ssio n  o f  p S 2 , there w as a 
s ig n ific a n tly  increased  rate o f  d isease recurrence in  the p o p u latio n  o f  patients w ho 
re ce ive d  trastuzum ab com pared to those w ho d id  not. S im ila r ly , in  a  sm a lle r cohort 
o f  patients w ho re ce ive d  trastuzum ab treatm ent p rio r to su rg ery, the e xp ressio n  o f 
p S 2  w as m a rke d ly  increased  in  the post-treatm ent specim ens com pared to the in it ia l 
b io p sy  sp ecim ens. Sam p les fro m  a  case-m atched  co ntro l w ho rece ive d  neo adjuvant 
chem otherapy d id  not show  a change in  e xp re ssio n  le v e ls  co n firm in g  that the 
d iffe re n ce  noted w as not as a re su lt o f  the chem otherapeutic agents.
M u ltip le  ran d o m ised  co n tro lle d  tria ls  have show n the b en e fit o f  trastuzum ab therapy 
on  d isease  free su rv iv a l and o v e ra ll su rv iv a l in  patients both w ith  m etastatic H E R 2
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p o sitiv e  breast can cer (S la m o n , L e y la n d -Jo n e s et a l. 20 0 1 ; M arty, C o gn etti et a l. 
2 0 0 5 ) and in  the ad ju van t settin g (R o m o n d , P e re z et a l. 2 0 0 5 ; Sm ith , P ro cter et a l. 
20 0 7 ; Jo en su u , B o n o  et a l. 2 0 0 9 ). N eo ad ju van t chem otherapy in  co n ju n ctio n  w ith  
neo adjuvant and ad ju van t trastuzum ab has a lso  re ce n tly  been show n to im pro ve 
p ro g n o sis in  lo c a lly  advanced  or in flam m ato ry breast can cer w hen com pared to 
n eo adjuvant chem otherapy alone (3 -ye a r event-free su rv iv a l, 7 1 %  [9 5 %  C l  61— 78; 
n =3 6  events] w ith  trastuzum ab, vs 5 6 %  [46— 65; n=51 events] w ithout; hazard  ratio 
0-59 [9 5 %  C l  0-38— 0 -9 0 ]; p = 0 -0 1 3 ) (G ia n n i, E ie rm a n n  et a l. 20 1 0 ). W h ile  the 
b en e fit o f  trastuzum ab in  the treatm ent o f  H E R 2  p o sitiv e  m etastatic or lo c a lly  
advanced breast can cer is  in d isp u tab le , the tim in g  o f  therapeutic regim es is  not as 
cle a r cut. T h e  tim in g  o f  trastuzum ab therap y in  re la tio n  to chem otherapy has been 
in ve stigate d  in  a  num ber o f  phase I I  and I I I  c lin ic a l tria ls , h ow ever there has yet to 
date been a la rg e  ran d o m ised  co n tro lled  tr ia l a sse ssin g  the im p act o f  trastuzum ab 
treatm ent w ith  co ncu rrent vs sequential h o rm onal therapy. The re fo re , it  rem ains 
u n cle ar w hether trastuzum ab sh o u ld  precede, be added to or fo llo w  horm onal 
therapy in  the subgroup  o f  patients w ho have H E R 2  p o sitiv e , E R  p o sitive  breast 
can cer. O ne random ised  co n tro lle d  tria l has lo o ke d  at the a d d itio n  o f  trastuzum ab to 
an arom atase in h ib ito r in  m etastatic d isease and fo u n d  that th is  p ro longed  
p ro g ressio n -fre e  s u rv iv a l (K a u fm a n , M a cke y  et a l. 2 0 0 9 ). H o w e ver, the tria l d id  not 
com pare co ncurrent therapy w ith  sequential therapy (trastuzum ab fo llo w e d  b y an 
arom atase in h ib ito r), trastuzum ab m onotherapy or the use o f  chem otherapeutic 
agents in  th is patient p o p u latio n .
A s  p re v io u sly  d iscu sse d , the resu lts in  th is chapter id e n tify  an increased  rate o f  
d isease recurrence in  H E R 2  p o sitiv e , p S 2  e xp re ssin g  patients w ho re ce ive d  
trastuzum ab com pared to those w ho d id  not. W e h yp o th esise  that th is  increase  in  
d isease recurrence is , at le ast in  part, due to the e ffect o f  trastuzum ab on the stero id  
horm one pathw ay as p re v io u sly  dem onstrated in  vitro  in  chapter 3 , w ith  c e llu la r 
p la stic ity  a llo w in g  the tum our c e lls  to overcom e the e ffect o f  trastuzum ab on grow th 
and p ro life ra tio n  thro u gh  the adaptive  m echan ism s o f  c ro ssta lk  betw een the 
s ig n a llin g  path w ays. T h is  e ffe ct is  further dem onstrated w hen tissu e  sam ples w ere 
com pared fro m  patients before and after they re ce ive d  trastuzum ab w ith  a d e fin itive  
increase  in  the e xp re ssio n  le v e ls  o f  p S 2  fo llo w in g  treatm ent noted, aga in
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h ig h lig h tin g  the e ffect o f  trastuzum ab on the a c tiv ity  o f  the stero id  horm one 
pathw ay.
T h e se  fin d in g s  su ggest a  re la tio n sh ip  betw een trastuzum ab treatm ent and a ctiv ity  o f  
the steroid  horm one path w ay that has not p re v io u sly  been in vestigate d  to a 
s ig n ific a n t extent in  p re -c lin ic a l o r c lin ic a l tria ls . I f ,  as w e h yp o th esise , trastuzum ab 
increases a c tiv ity  o f  E R  th ro u gh  the stero id  horm one p athw ay, then current c lin ic a l 
p ractice  o f  treatm ent w ith  seq uen tia l therapy o f  ad ju van t trastuzum ab and 
chem otherapy fo llo w e d  b y h orm onal therapy does not prevent the u p regu latio n  o f 
the steroid  horm one path w ay b y  trastuzum ab. In  fa ct, it  co u ld  potentiate the 
p ro life ra tio n  o f  re sid u a l can cer c e lls  in  an u n co n tro lle d  m anner. W h ile  further 
research  is  required  to determ ine the m o le cu la r p ath w ay in v o lv e d  in  the cro ssta lk  
betw een the s ig n a llin g  p ath w ays, there is  a lso  the need to translate  our re su lts in  to 
the c lin ic a l arena to fu rth er in ve stig a te  our fin d in g s  in  a  la rg e r cohort o f  patients. 
Indeed, co ncurrent treatm ent o f  trastuzum ab w ith  an  a n ti-E R  agent su ch  as 
tam o xifen  m igh t negate the e ffe ct o f  trastuzum ab on the stero id  horm one pathw ay, a 
change in  the current therapeutic m anagem ent o f  breast can cer w h ich  w arrants 
further in ve stig a tio n .
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C h a p t e r  5
G eneral D iscussion
5.1 General Discussion
D esp ite  recent phenom enal ad vances in  both the detection  and treatm ent o f  breast 
can cer, it s t ill co ntinues to a ffe ct one in  ten w om en in  the w estern w o rld  and rem ains 
the le a d in g  cause o f  can cer-re lated  m o rta litie s in  w om en in  Ire la n d  today. T h is  is  due 
to a num ber o f  facto rs, not least the co m p le x nature o f  the d isease itse lf. Indeed, 
breast cancer is  n o w  not co nsid ered  to be a s in g le  d isease entity but rather a 
spectrum  o f  d iso rd ers that v a ry  im m e n se ly  in  d isease p ath o lo gy and p ro gressio n  
w h ich  can  a ffe ct response to treatm ents and o v e ra ll patient p ro g n o sis. T h e  a b ility  to 
id e n tify  patients w ho w o u ld  b en efit from  cu rre n tly  a v a ila b le  ad ju van t and 
neo adjuvant therap ies as w e ll as those fo r w hom  chem o and horm onal therapies 
w o u ld  have no b en efit s t ill rem ain s a  ch a lle n ge  fo r c lin ic ia n s  today. T o  date, the use 
o f  c lin ico p a th o lo g ica l param eters su ch  as receptor status and lym p h  node p o sitiv ity  
have been in va lu a b le  in  in fo rm in g  the c lin ic a l m anagem ent o f  breast cancer. The  
num ber and v a rie ty  o f  therap ies cu rre n tly  a v a ila b le  has increased  s ig n ific a n tly  over 
the la st tw o decades. H o w e ve r, due to the co m p le x nature o f  the d isease and an, as 
yet, incom plete  u n derstan d in g o f  the in tricate  re la tio n sh ip s am ong the va rio u s 
s ig n a llin g  pathw ays in v o lv e d , targeted therapy that is  selected  based on a p atient’s 
in d iv id u a l can cer is  not ye t p o ssib le .
In d eed, a s ig n ific a n t ch a lle n ge  that is  faced  b y c lin ic ia n s  and patients is  the 
developm ent o f  resistance  b y  can cers to therapeutic agents, w ith  a s ig n ific a n t 
num ber o f  patients w ith  go od  p ro g n o stic  tum our p ro file  d e ve lo p in g  recurrence that 
does not respond to firs t-lin e  therap ies. T h e  p la stic ity  o f  the can cer c e ll a llo w s it to 
adapt its  s ig n a llin g  m echan ism s to overcom e treatm ents re su ltin g  in  c e ll p ro life ra tio n  
and tum our recurrence that does not respond to the o rig in a l therap ies. T h e  ch a lle n ge  
s t ill rem ain s to d eve lo p  the a b ility  to in d iv id u a lise  treatm ent regim es acco rd in g  to 
tum our ch a ra cte ristics re su ltin g  in  m axim u m  patient b en efit w ith  m in im a l co -m o rb id  
e ffects and decreased r is k  o f  resistan ce  d e ve lo p in g. E lu c id a tio n  o f  the m echanism s 
o f  h o w  a tum our ca n  adapt to therapy and co nseq u en tly re o ccu r w ill p ro vid e  
m e c h a n istic a lly  targeted therap ies w h ich  w ill p o s itiv e ly  im p act patient p ro gn o sis and 
su rv iv a l.
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O ne m echan ism  b y  w h ich  E R  p o sitiv e  tum ours are tho ught to d eve lo p  resistance  to 
h o rm onal therap ies such  as tam o xife n  is  through  cro ssta lk  betw een the stero id  
horm one pathw ay and the gro w th  fa cto r receptor pathw ay. V a rio u s p rotein  kin ases 
h ave  been im p licate d  in  th is  c ro ssta lk  in c lu d in g  S rc  (R a za n d i, Pedram  et a l. 2 0 0 3 ), 
E R K 1  and E R K 2  (K a to , E n d o h  et a l. 1995; R a za n d i, Pedram  et a l. 2 0 0 3 ), P I3 K  
(C a m p b e ll, B h a t-N a k sh a tri et a l. 2 0 0 1 ) and P 9 0 R S K  (Jo e l, S m ith  et a l. 1998) am ong 
others, w ith  p re c lin ic a l stu d ies co n firm in g  the asso cia tio n  o f  tam o xifen  resistance 
w ith  increased  le v e ls  o f  v a rio u s k in a se s (S c h iff, R e d d y  et a l. 20 0 0 ).
W ith  cro ssta lk  betw een the tw o s ig n a llin g  pathw ays p la y in g  a s ig n ific a n t ro le  in  
resistan ce  to endocrine th erap y, w e h ypothesised  that it  m ust a lso  p la y  a part in  the 
developm ent o f  resistance  to a n ti-H E R 2  therap ies su ch  as trastuzum ab. P re v io u s 
w o rk  b y  X ia  et a l h as im p lica te d  E R  s ig n a llin g  in  the developm ent o f  resistance  by 
b reast cancer c e lls  to la p a tin ib , a therapeutic target o f  E G F R  and H E R 2  (X ia , B a cu s 
et a l. 2 0 0 6 ). W e therefore determ ined to fu rth er e lu cid ate  the p o ss ib ility  o f  cro ssta lk  
p la y in g  a ro le  in  the developm ent o f  resistance  to trastuzum ab.
O u r firs t  a im  w as to in ve stig a te  our h yp o th e sis in vitro  u s in g  breast cancer c e ll 
m o d els to re p licate  v a rio u s tum our phenotypes (chapter 3 ). A s  suspected, treatm ent 
o f  endocrine se n sitive  M C F 7  c e lls  w ith  trastuzum ab resu lted  in  the u p regu latio n  o f 
the stero id  horm one p athw ay. S im ila r  u p regu latio n  w as not observed in  the 
end o crine  in se n sitiv e  L C C 1  c e lls  su g ge stin g  that trastuzum ab m ig h t o n ly  in flu en ce  
the stero id  horm one path w ay in  the presence o f oestrogen se n sitive  E R . H o w ever, 
fu rth er m o le cu la r research  is  required  to in ve stigate  th is h yp o th e sis. Subsequent 
im m u n o h isto ch em ica l a n a ly s is  o f  patient tum our sam ples lo o k in g  sp e c ific a lly  at the 
a c tiv ity  o f  the stero id  horm one pathw ay found  a s ig n ific a n t increase in  the rate o f 
d isease  recurrence in  H E R 2  p o sitiv e  patients w ho re ce ive d  trastuzum ab com pared to 
those w ho d id  not (ch ap ter 4 ). W e a lso  observed increased  le v e ls  o f  p S 2  e xp ressio n  
in  a separate co ho rt o f  p atie n t’ s tissu e  sam ples fo llo w in g  treatm ent w ith  trastuzum ab. 
T h is , in  co n ju n ctio n  w ith  the p re v io u sly  describ ed  in v itro  fin d in g s  lends credence to 
our h yp o th esis that trastuzum ab can  d rive  a ctiv ity  thro u gh  the stero id  horm one 
p ath w ay, in cre a sin g  E R  fu n ctio n  le a d in g  to c e ll p ro life ra tio n  and tum our grow th.
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A  second fin d in g  fro m  our in v itro  research  w as the e xp re ssio n  o f  a  fu n ctio n a l E R  in  
a w e ll estab lish ed  E R  n egative  breast can cer c e ll lin e  fo llo w in g  trastuzum ab 
treatm ent (chapter 3 ). E p ig e n e tic  m o d ifica tio n s have been show n to p la y  a 
s ig n ific a n t ro le  in  E R  gene e xp re ssio n  (O ttav ian o , Issa  et a l. 1994; Y a n g , Fe rg u so n  
et a l. 2 0 0 0 ). In  both norm al and the m a jo rity  o f  E R  p o sitive  breast can cer c e ll lin e s, 
the E R  C p G  isla n d  h as been show n to be unm ethylated, w hereas it  is  m ethylated in  
m ost E R  n egative  breast can cer c e ll lin e s (La p id u s, N a ss et a l. 1998). R ed uced  or 
absent E R  e xp re ssio n  is  a re su lt o f  m eth ylatio n  o f  these C p G  is la n d s and can  be 
reversed  thro u gh  d em eth ylatio n  (F e rg u so n , La p id u s et a l. 1995). W e co nfirm ed  that 
the e xp re ssio n  o f  E R  fo llo w in g  trastuzum ab treatm ent w as due to dem ethylation  o f  
the C p G  is la n d s w ith in  the E R  prom oter regio n .
T h e  presence o f cro ssta lk  betw een the stero id  horm one and gro w th  facto r receptor 
p ath w ays re fle cts the p la s tic ity  o f  tum our c e lls  and the ir a b ility  to upregulate 
receptors to counteract the treatm ents used to com bat them . W hether th is m echanism  
has the potential to o ccu r in  a ll tum our c e lls  or w ith in  a se le ct fe w  is  not yet 
determ ined. B y  the latter p ro ce ss, treatm ent w ith  ce rta in  therapeutic agents su ch  as 
trastuzum ab w o u ld  re su lt in  the death o f tum our c e lls  that are se n sitive  to H E R 2  
receptor in h ib itio n . H o w e ve r, it  w o u ld  fa c ilita te  the d iffe re n tia tio n  o f  certa in  ce lls  
that po ssess the a b ility  to p ro life ra te  through  receptor c ro ssta lk  thereby a llo w in g  
tum our grow th in  the presence o f  supposed appropriate therap ies. W hether the 
phenom enon o ccu rs th ro u gh  the form er o r latter m echan ism  is  beyo nd the rem it o f  
th is  th esis h ow ever it  does w arran t fu rth er in ve stig a tio n  in  future w o rk. O u r resu lts 
have id e n tifie d  the phenom enon o f  receptor cro ssta lk  and so ra ise  the question  o f 
h ow  to ta ck le  th is prob lem  w ith in  c lin ic a l p ractice .
T h e  firs t  issu e  that is  ra ised  is  the tim in g  o f  therapeutic in terven tio n s, p a rtic u la rly  in  
H E R 2  p o sitive , E R  p o sitiv e  tum ours. C u rre n tly , c lin ic a l p ractice  is  to treat su itab le  
H E R 2  p o sitiv e  patients w ith  trastuzum ab co n cu rre n tly  w ith  ad ju van t chem otherapy 
w ith  sequentia l ta m o xife n  or other anti-o estro gen  therapy. H o w e ver, our resu lts 
w o u ld  propose that th is  w o u ld  re su lt in  u n co n tro lled  stim u latio n  o f  the steroid  
horm one pathw ay and therefore  co ncurrent treatm ent o f  trastuzum ab w ith  an  an ti­
oestrogen therapy w o u ld  be p re fere n tia l. T h e  co m b in atio n  o f  trastuzum ab w ith  the 
arom atase in h ib ito r an astro zo le  has been show n to im p ro ve  p ro g re ssio n  free su rv iv a l
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in  patients w ith  m etastatic breast ca n ce r (K a u fm a n , M a cke y  et a l. 2 0 0 9 ), how ever, as 
p re v io u sly  d iscu sse d  in  chapter 4 , there w ere a  num ber o f  lim ita tio n s to th is study. 
T h e re  are a num ber o f  c lin ic a l tr ia ls  cu rre n tly  underw ay w h ich  are a sse ssin g  the 
e ffe ct o f  co ncurrent trastuzum ab and an ti-o e stro gen  treatm ents (N CT00022672 ; 
N CT00238290 ; N C T00499681) w h ich  sh o u ld  help  to determ ine the benefit o f  
co ncurrent vs sequentia l treatm ent. N o t a ll tum ours are lik e ly  to pro gress and relapse 
d u rin g  trastuzum ab treatm ent therefore the use o f  co ncurrent treatm ent is  
u n ne cessary in  a num ber o f  patients. Fu rth e r research  is  required  to id e n tify  
ch a ra cte ristic  tum our m arkers w h ich  w o u ld  be ab le  to d istin g u ish  cancers re q u irin g  
co ncu rrent therapy due to th e ir p re d isp o sitio n  to recurrence thro u gh  cro ssta lk  from  
those w ho are le ss lik e ly  to reoccur.
T h e  second issu e  re lates to our o b se rvatio n  that trastuzum ab treatm ent can  re su lt in  
the e xp ressio n  o f  a fu n ctio n a lly  a ctive  E R  in  E R  n egative  breast cancer c e lls . T h is  
ra ise s the question  o f  the need fo r an ti-o estro gen  therapy in  patients w ith  E R  
n egative  tum ours w ho are re ce iv in g  trastuzum ab therapy. C u rre n tly , i f  a tum our is  
fo u n d  not to express E R , then the patient does not re ce ive  an ti-o estro gen  therapy, 
re ga rd le ss o f  H E R 2  status. H o w e ve r, i f  trastuzum ab treatm ent w as to resu lt in  the re ­
e xp re ssio n  o f  E R  then these tum ours w o u ld  be ab le  to p ro life rate  due to the 
u n co n tro lled  a ctiv ity  o f  the stero id  horm one pathw ay. It  is  c le a r that not a ll patients 
w ith  E R  n egative  H E R 2  p o sitiv e  tum ours d evelo p  re -e xp re ssio n  o f  E R  fo llo w in g  
trastuzum ab treatm ent or e lse  there w o u ld  have been evid en ce  o f  such  a phenom enon 
w ith in  the m u ltip le  c lin ic a l tria ls  a sse ssin g  the e ffic a c y  o f  trastuzum ab. O u r fin d in g s 
su g ge st that a  p ro p o rtio n  o f  E R  n eg ative  breast can cers w ill exp ress a fu n ctio n a l E R  
fo llo w in g  trastuzum ab therapy. Sh o u ld  a ll patients w ith  E R  n egative  tum ours re ce ive  
an ti-o estro gen  therapy despite th e ir E R  status i f  they are to re ce ive  trastuzum ab? 
W h ile  th is  w ill in e v ita b ly  be b e n e fic ia l in  a num ber o f  p atients, it  w o u ld  re su lt in  the 
over-treatm ent o f  patients in  w hom  E R  e xp ressio n  does not o ccu r fo llo w in g  
treatm ent. T h is  has both fin a n c ia l im p lic a tio n s in  re la tio n  to healthcare expenditure 
and a lso  co u ld  p o te n tia lly  re su lt in  un necessary sid e  e ffects o f  anti-oestrogen  
therapy. T h e  n ext step therefore is  to e lu cid ate  the m echan ism  b y  w h ich  trastuzum ab 
can  cause dem ethylation  o f  the C p G  is la n d s w ith in  the prom oter re g io n  o f the E R  
gene to e lic it  a p o ten tia l b io m arke r that w o u ld  enable c lin ic ia n s  to id e n tify  patients 
in  w hom  anti-o estro gen  therapy w o u ld  be b e n e fic ia l.
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In  fa ct, receptor cro ssta lk  re su ltin g  in  re -exp ressio n  o f  E R  in  E R  n egative  tum ours is  
a m echan ism  that can  be used to a p atient’ s advantage. H o rm one receptor status is  an 
im portant p ro gn o stic in d ica to r in  o v e ra ll and d isease free su rv iv a l rates w ith  E R  
p o sitiv e  tum ours p erfo rm in g s ig n ific a n tly  better than E R  n egative  tum ours. T h e  
a b ility  to re-activate  E R  and therefore co nvert an E R  n egative  can cer into  an E R  
p o sitive  one w o u ld  o ffe r c lin ic ia n s  a therapeutic target through w h ich  they can  
co n tro l c e ll grow th and tum our recurrence. T h e  a b ility  to id e n tify  th is  su b -p o p u latio n  
o f  patients w o u ld  gre atly  enhance therapeutic in terven tio n s and im p ro ve  patient 
p ro g n o sis. In  fa ct, it  m igh t w iden  the subset o f  patients in  w hom  trastuzum ab is  
p re scrib e d  from  current p ractices o f  treatin g patients w ith  m etastatic or lym p h  node 
p o sitiv e  d isease o n ly , to in c lu d e  those w ith  E R  n egative  lo c a l d isease in  w hom  
trastuzum ab has been id e n tifie d  to re su lt in  a sw itch  in  E R  status thereby fa c ilita tin g  
broader therapeutic intervention .
O u r fin d in g s  o f  receptor c ro ssta lk  and in  p a rticu la r the e xp re ssio n  o f  E R  fo llo w in g  
trastuzum ab therapy ra ise s questio n s re ga rd in g  the a n a ly s is  o f  tum our specim ens to 
determ ine receptor status. C u rre n tly  receptor status is  based upon the p rim ary 
resectio n  specim en w ith  m etastatic d isease not ro u tin e ly  b io p sie d  u n less it  is  a 
lo c a lly  recurrent or cutaneous le sio n . H o w e ve r, i f  a p roportion  o f  E R  negative  
tum ours sw itch  E R  status fo llo w in g  ad ju van t trastuzum ab treatm ent, th is w ill resu lt 
in  a num ber o f  patients w ith  m etastatic d isease fa ilin g  to re ce ive  appropriate 
horm onal therapy. In  fa ct, a p ro sp e ctive  study co m p arin g the receptor status o f 
d istant m étastasés w ith  that o f  the p rim a ry  breast cancer found  that there w as a 
su b stan tia l d isco rd an ce  re su ltin g  in  altered m anagem ent in  2 0 %  o f  cases (S im m o n s, 
M ille r  et a l. 2 0 0 9 ). C lin ic a l m anagem ent o f  patients w ith  m etastatic d isease therefore 
needs to co n sid e r the p o ss ib ility  o f  receptor cro ssta lk  re su ltin g  in  a change in  
receptor status w ith  a p o ssib le  need fo r a m ore a gg re ssive  b io p sy  p o lic y  o f  a cce ssib le  
m étastasés u n til m o le cu la r stud ies can id e n tify  p rim ary tum ours in  w h ich  receptor 
status is  lik e ly  to sw itch .
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5.2 Conclusion
T h e  p la s tic ity  o f  breast can cer and its  a b ility  to overcom e therapeutic in terven tio n s 
thro u gh  receptor cro ssta lk  as w e ll as its  ca p a c ity  to alter receptor status dem onstrates 
the co m p le x  m o le cu la r m echan ism s in v o lv e d  in  the d isease p ro cess and h ig h lig h ts  
the need fo r fu rth er research  to u n co ve r the re levan t m echan istie s. T h e  w o rk  
co ntained  w ith in  th is  th e sis h as u n co vered  the p rim ary step in  u n ra v e llin g  th is 
co m p le x  p ath w ay in te ractio n . W e have dem onstrated the a b ility  o f  trastuzum ab to 
in flu e n ce  the stero id  horm one p ath w ay thereby fa c ilita tin g  tum our recurrence 
th ro u gh  receptor cro ssta lk  w h ich  w e h ave  show n had a n egative  im p act on d isease 
recurrence w ith in  our patient p o p u latio n . W e have a lso  fo r the firs t  tim e 
dem onstrated the a b ility  o f  a gro w th  fa cto r receptor in h ib ito r to a lter the e xp ressio n  
o f  E R  thro u gh  e p ige n etic m o d ifica tio n  o f  the gene prom oter re g io n . T h e  fin d in g s 
presented in  th is  w o rk  constitute a sm a ll fragm en t o f  a la rge  and e x c itin g  p u zzle . Th e  
un d erstan d in g o f  the co m p le x re la tio n sh ip  betw een the stero id  horm one and grow th 
fa cto r receptor p ath w ays is  lik e ly  to present a  s ig n ific a n t ch a lle n ge  to academ ics and 
c lin ic ia n s  fo r m an y ye ars. H o w e ve r, e ve ry  p ie ce  o f  the p u zz le  takes us one step 
c lo se r to u n derstan d in g the b io lo g y  o f  th is  d isease and therefore enables us to 
im p ro ve  therapeutic o p tio n s and u ltim a te ly  benefits the patient.
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7 Appendix I
7.1 Cell Culture
T ry p s in -E D T A
Tryps in  10 X  liq u id  (25g/l G iB c o B R L ® )
HBSS (G iB co B R L ® )
0.02%  E D T A  
2 0 M M  HEPES
1 m l o f  tryps in  and 1 m l o f  0.02%  E D T A  was made up to 10m l HBSS filte r  p rio r to 
use through A c ro d ic®  32 filte rs  (0 .2 jim  pore size)
T re a tm e n t c o n d itio n s
17p-estradiol (E?)
4 -hydroxy tam ox ifen  (4 -O H T )
Trastuzum ab 
C ontro l
P h o sp h a te  b u ffe re d  sa lin e  ( P B S )
D issolve one PBS tablet per 200m ls dl-bO 
Each PBS tablet contains:
0.01M  phosphate bu ffe r 
0.0027M  potassium ch lo ride  
0.137M  sodium  ch lo ride  
A utoc lave  and filte r  p rio r to use
10 '8M  concentration 
10‘8M  concentration 
100(.iM/ml concentration 
Sterile water
I
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7.2 Western blot analysis
P ro te in  s ta n d a rd s  u sed  to  cre a te  th e  s ta n d a rd  c u rv e  fo r  B C A  a ssa y
Standard Stock A lbum in  
(fil)
dH20
(MO
Protein Concentration 
(fig/m l)
A 0 100 0
B 10 90 200
C 20 80 400
D 30 70 600
E 40 60 800
F 50 50 1000
G 60 40 1200
H 70 30 1400
R a d io im m u n o p re c ip ita t io n  a ssa y  ( R IP A )  ly s is  b u ffe r
l x  P B S  4 9 5 m ls
1 %  Ip e  5m ls
0 .5 %  D e o xych o la te  2 .5 g  
0 .1 %  S D S  0 .5 g
T r is  b u ffe re d  sa lin e  ( T B S )  (2 0 X )
121.1 g T r is
175.5 g N a C l
M ade up to 1 litre  w ith  d H 2 0  
U se  at I X  fin a l co ncen tratio n , p H  8.3
W a sh  b u ffe r  ( T B S - T )
l x  T B S
0 .0 5 %  T rito n  X - 100
1 M  T r is - H C l,  p H  6.8
1 5 7 .6 g T r is -H C l
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I
Made up to 1 litre with dE^O, pH 6.8
1.5  M  T r is .H C I ,  p H  8.8
2 3 6 .4 g  T r is -  H C 1
M ade up to 1 litre  w ith  d H 2 0 , p H  8.8
B lo c k in g  b u ffe r
I X  T B S
0 .0 5 %  T r ito n ®  X -1 0 0  
5 %  M o le cu la r grade sk im m ed  m ilk
T r a n s fe r  b u ffe r:
2.93 G ly c in e
5.8 g  T r is  B ase
0.375 g  S D S
20 0 n iL  M ethanol
M ade up to I litre  w ith  d H 2 0
S a m p le  b u ffe r  (5 X )
2 g  S D S
5 m l 1M  T r is .H C I (6 .8 )
3 .0  m l d H 2 0  
8 M L  G ly c e ro l
2 m l 0 .1 %  B rom ophenol B lu e  
M ake up to 20 m l w ith  d H 2 0  
5 %  B -m ercaptom elhanol
R u n n in g  b u ffe r  (1 0 X )
288 gm  G ly c in e  
60 .6  g T r is  B ase  
20 g  S D S
M ade up to 2 litre s w ith  d l-120
1 0 0
A c ry la m id e / B is -a c ry la m id e  3 0 %
L iq u id  e a sig e l 3 0 %  (w /v) a cry la m id e , 0 .8 %  (w /v) b is-a cry la m id e  w as used 
d ire c tly
2 0 %  S D S
20 g  S D S  w as d isso lv e d  in  100 m l o f  d H 2 0
1 0 %  A m m o n iu m  P e rsu lp h a te
100 m g/m l w as d isso lv e d  in  d H 2 0
7.3 N u c le ic  a c id  b io c h e m istry
1 0 x T r is  ace ta te  E D T A  b u ffe r , p H  8 .0
4 8 .4 g  T r is
11.4m l g la c ia l a ce tic a c id
2 0 m l 0 .5 M  E D T A
M ade up to 1 litre  w ith  dE^O , p H  8.0
7 .4  Im m u n o h is to c h e m istry
S o d iu m  c itra te  b u ffe r, p H  6.0
2 .9 4 g  lO m M  so d iu m  citrate
5 0 0 p l 0 .0 5 %  T w e e n
M ade up to  1 litre  w ith  dH zO , p H  6.0
1 0 1
